1
|
Shalmani AA, Wang A, Ahmed Z, Sheybanifard M, Mihyar R, Buhl EM, Pohl M, Hennink WE, Kiessling F, Metselaar JM, Shi Y, Lammers T, Peña Q. Tunable polymeric micelles for taxane and corticosteroid co-delivery. Drug Deliv Transl Res 2023:10.1007/s13346-023-01465-x. [PMID: 37962836 DOI: 10.1007/s13346-023-01465-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/22/2023] [Indexed: 11/15/2023]
Abstract
Nanomedicine holds promise for potentiating drug combination therapies. Increasing (pre)clinical evidence is available exemplifying the value of co-formulating and co-delivering different drugs in modular nanocarriers. Taxanes like paclitaxel (PTX) are widely used anticancer agents, and commonly combined with corticosteroids like dexamethasone (DEX), which besides for suppressing inflammation and infusion reactions, are increasingly explored for modulating the tumor microenvironment towards enhanced nano-chemotherapy delivery and efficacy. We here set out to develop a size- and release rate-tunable polymeric micelle platform for co-delivery of taxanes and corticosteroids. We synthesized amphiphilic mPEG-b-p(HPMAm-Bz) block copolymers of various molecular weights and used them to prepare PTX and DEX single- and double-loaded micelles of different sizes. Both drugs could be efficiently co-encapsulated, and systematic comparison between single- and co-loaded formulations demonstrated comparable physicochemical properties, encapsulation efficiencies, and release profiles. Larger micelles showed slower drug release, and DEX release was always faster than PTX. The versatility of the platform was exemplified by co-encapsulating two additional taxane-corticosteroid combinations, demonstrating that drug hydrophobicity and molecular weight are key properties that strongly contribute to drug retention in micelles. Altogether, our work shows that mPEG-b-p(HPMAm-Bz) polymeric micelles serve as a tunable and versatile nanoparticle platform for controlled co-delivery of taxanes and corticosteroids, thereby paving the way for using these micelles as a modular carrier for multidrug nanomedicine.
Collapse
Affiliation(s)
- Armin Azadkhah Shalmani
- Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, Forckenbeckstrasse 55, 52074, Aachen, Germany
| | - Alec Wang
- Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, Forckenbeckstrasse 55, 52074, Aachen, Germany
| | - Zaheer Ahmed
- Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, Forckenbeckstrasse 55, 52074, Aachen, Germany
| | - Maryam Sheybanifard
- Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, Forckenbeckstrasse 55, 52074, Aachen, Germany
| | - Rahaf Mihyar
- Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, Forckenbeckstrasse 55, 52074, Aachen, Germany
| | - Eva Miriam Buhl
- Electron Microscopy Facility, Institute of Pathology, RWTH University Hospital, Pauwelsstrasse 30, 52074, Aachen, Germany
| | - Michael Pohl
- DWI - Leibniz-Institute for Interactive Materials, Forckenbeckstrasse 50, 52074, Aachen, Germany
| | - Wim E Hennink
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, 3508 TB, Utrecht, The Netherlands
| | - Fabian Kiessling
- Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, Forckenbeckstrasse 55, 52074, Aachen, Germany
| | - Josbert M Metselaar
- Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, Forckenbeckstrasse 55, 52074, Aachen, Germany
| | - Yang Shi
- Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, Forckenbeckstrasse 55, 52074, Aachen, Germany
| | - Twan Lammers
- Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, Forckenbeckstrasse 55, 52074, Aachen, Germany.
| | - Quim Peña
- Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, Forckenbeckstrasse 55, 52074, Aachen, Germany.
| |
Collapse
|
2
|
Shalmani AA, Ahmed Z, Sheybanifard M, Wang A, Weiler M, Buhl EM, Klinkenberg G, Schmid R, Hennink W, Kiessling F, Metselaar JM, Lammers T, Peña Q, Shi Y. Effect of Radical Polymerization Method on Pharmaceutical Properties of Π Electron-Stabilized HPMA-Based Polymeric Micelles. Biomacromolecules 2023; 24:4444-4453. [PMID: 36753733 DOI: 10.1021/acs.biomac.2c01261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Abstract
Polymeric micelles are among the most extensively used drug delivery systems. Key properties of micelles, such as size, size distribution, drug loading, and drug release kinetics, are crucial for proper therapeutic performance. Whether polymers from more controlled polymerization methods produce micelles with more favorable properties remains elusive. To address this question, we synthesized methoxy poly(ethylene glycol)-b-(N-(2-benzoyloxypropyl)methacrylamide) (mPEG-b-p(HPMAm-Bz)) block copolymers of three different comparable molecular weights (∼9, 13, and 20 kDa), via both conventional free radical (FR) and reversible addition-fragmentation chain transfer (RAFT) polymerization. The polymers were subsequently employed to prepare empty and paclitaxel-loaded micelles. While FR polymers had relatively high dispersities (Đ ∼ 1.5-1.7) compared to their RAFT counterparts (Đ ∼ 1.1-1.3), they formed micelles with similar pharmaceutical properties (e.g., size, size distribution, critical micelle concentration, cytotoxicity, and drug loading and retention). Our findings suggest that pharmaceutical properties of mPEG-b-p(HPMAm-Bz) micelles do not depend on the synthesis route of their constituent polymers.
Collapse
Affiliation(s)
- Armin Azadkhah Shalmani
- Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074 Aachen, Germany
| | - Zaheer Ahmed
- Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074 Aachen, Germany
| | - Maryam Sheybanifard
- Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074 Aachen, Germany
| | - Alec Wang
- Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074 Aachen, Germany
| | - Marek Weiler
- Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074 Aachen, Germany
| | - Eva Miriam Buhl
- Electron Microscopy Facility, Institute of Pathology, RWTH University Hospital, 52074 Aachen, Germany
| | - Geir Klinkenberg
- Department of Biotechnology and Nanomedicine, SINTEF Industry, 7034, Trondheim, Norway
| | - Ruth Schmid
- Department of Biotechnology and Nanomedicine, SINTEF Industry, 7034, Trondheim, Norway
| | - Wim Hennink
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, 3508 TB Utrecht, The Netherlands
| | - Fabian Kiessling
- Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074 Aachen, Germany
| | - Josbert M Metselaar
- Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074 Aachen, Germany
| | - Twan Lammers
- Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074 Aachen, Germany
| | - Quim Peña
- Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074 Aachen, Germany
| | - Yang Shi
- Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074 Aachen, Germany
| |
Collapse
|
3
|
Sheybanifard M, Guerzoni LPB, Omidinia-Anarkoli A, De Laporte L, Buyel J, Besseling R, Damen M, Gerich A, Lammers T, Metselaar JM. Liposome manufacturing under continuous flow conditions: towards a fully integrated set-up with in-line control of critical quality attributes. Lab Chip 2022; 23:182-194. [PMID: 36448477 DOI: 10.1039/d2lc00463a] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/17/2023]
Abstract
Continuous flow manufacturing (CFM) has shown remarkable advantages in the industrial-scale production of drug-loaded nanomedicines, including mRNA-based COVID-19 vaccines. Thus far, CFM research in nanomedicine has mainly focused on the initial particle formation step, while post-formation production steps are hardly ever integrated. The opportunity to implement in-line quality control of critical quality attributes merits closer investigation. Here, we designed and tested a CFM setup for the manufacturing of liposomal nanomedicines that can potentially encompass all manufacturing steps in an end-to-end system. Our main aim was to elucidate the key composition and process parameters that affect the physicochemical characteristics of the liposomes. Total flow rate, lipid concentration and residence time of the liposomes in a high ethanol environment (i.e., above 20% v/v) emerged as critical parameters to tailor liposome size between 80 and 150 nm. After liposome formation, the pressure and the surface area of the filter in the ultrafiltration unit were critical parameters in the process of clearing the dispersion from residual ethanol. As a final step, we integrated in-line measurement of liposome size and residual ethanol content. Such in-line measurements allow for real-time monitoring and in-process adjustment of key composition and process parameters.
Collapse
Affiliation(s)
- Maryam Sheybanifard
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany.
| | - Luis P B Guerzoni
- DWI Leibniz Institute for Interactive Materials, Forckenbeckstrasse 50, 52074 Aachen, Germany
| | - Abdolrahman Omidinia-Anarkoli
- DWI Leibniz Institute for Interactive Materials, Forckenbeckstrasse 50, 52074 Aachen, Germany
- Institute of Applied Medical Engineering, RWTH University, Pauwelsstraße 20, 52074 Aachen, Germany
| | - Laura De Laporte
- DWI Leibniz Institute for Interactive Materials, Forckenbeckstrasse 50, 52074 Aachen, Germany
- Institute of Applied Medical Engineering, RWTH University, Pauwelsstraße 20, 52074 Aachen, Germany
- Institute for Technical and Macromolecular Chemistry, RWTH Aachen, Worringerweg 1-2, 52074 Aachen, Germany
| | - Johannes Buyel
- Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Forckenbeckstrasse 6, 52074 Aachen, Germany
- Institute for Molecular Biotechnology, RWTH Aachen University, Worringerweg 1, 52074 Aachen, Germany
- Institute of Bioprocess Science and Engineering, University of Natural Resources and Life Sciences (BOKU), Muthgasse 18, A-1190 Vienna, Austria
| | - Rut Besseling
- InProcess-LSP, Kloosterstraat 9, 5349 AB Oss, The Netherlands
| | - Michiel Damen
- InProcess-LSP, Kloosterstraat 9, 5349 AB Oss, The Netherlands
| | - Ad Gerich
- InProcess-LSP, Kloosterstraat 9, 5349 AB Oss, The Netherlands
| | - Twan Lammers
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany.
| | - Josbert M Metselaar
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany.
| |
Collapse
|
4
|
Peña Q, Wang A, Zaremba O, Shi Y, Scheeren HW, Metselaar JM, Kiessling F, Pallares RM, Wuttke S, Lammers T. Metallodrugs in cancer nanomedicine. Chem Soc Rev 2022; 51:2544-2582. [PMID: 35262108 DOI: 10.1039/d1cs00468a] [Citation(s) in RCA: 47] [Impact Index Per Article: 23.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Metal complexes are extensively used for cancer therapy. The multiple variables available for tuning (metal, ligand, and metal-ligand interaction) offer unique opportunities for drug design, and have led to a vast portfolio of metallodrugs that can display a higher diversity of functions and mechanisms of action with respect to pure organic structures. Clinically approved metallodrugs, such as cisplatin, carboplatin and oxaliplatin, are used to treat many types of cancer and play prominent roles in combination regimens, including with immunotherapy. However, metallodrugs generally suffer from poor pharmacokinetics, low levels of target site accumulation, metal-mediated off-target reactivity and development of drug resistance, which can all limit their efficacy and clinical translation. Nanomedicine has arisen as a powerful tool to help overcome these shortcomings. Several nanoformulations have already significantly improved the efficacy and reduced the toxicity of (chemo-)therapeutic drugs, including some promising metallodrug-containing nanomedicines currently in clinical trials. In this critical review, we analyse the opportunities and clinical challenges of metallodrugs, and we assess the advantages and limitations of metallodrug delivery, both from a nanocarrier and from a metal-nano interaction perspective. We describe the latest and most relevant nanomedicine formulations developed for metal complexes, and we discuss how the rational combination of coordination chemistry with nanomedicine technology can assist in promoting the clinical translation of metallodrugs.
Collapse
Affiliation(s)
- Quim Peña
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, 52074, Aachen, Germany.
| | - Alec Wang
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, 52074, Aachen, Germany.
| | - Orysia Zaremba
- BCMaterials, Bld. Martina Casiano, 3rd. Floor, UPV/EHU Science Park, 48940, Leioa, Spain
| | - Yang Shi
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, 52074, Aachen, Germany.
| | - Hans W Scheeren
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, 52074, Aachen, Germany.
| | - Josbert M Metselaar
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, 52074, Aachen, Germany.
| | - Fabian Kiessling
- Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, 52074, Aachen, Germany
| | - Roger M Pallares
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, 52074, Aachen, Germany.
| | - Stefan Wuttke
- BCMaterials, Bld. Martina Casiano, 3rd. Floor, UPV/EHU Science Park, 48940, Leioa, Spain.,Ikerbasque, Basque Foundation for Science, Bilbao, Spain.
| | - Twan Lammers
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, 52074, Aachen, Germany.
| |
Collapse
|
5
|
Wong CW, Wong E, Metselaar JM, Storm G, Wong TT. Liposomal drug delivery system for anti-inflammatory treatment after cataract surgery: a phase I/II clinical trial. Drug Deliv Transl Res 2022; 12:7-14. [PMID: 33569720 DOI: 10.1007/s13346-021-00912-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/15/2021] [Indexed: 12/20/2022]
Abstract
Liposomes as a drug delivery system may overcome the problems associated with non-compliance to eyedrops and inadequate control of inflammation after cataract surgery. We evaluated the safety and efficacy of a single subconjunctival injection of liposomal prednisolone phosphate (LPP) for the treatment of post-cataract surgery inflammation. This is a phase I/II, open-label non-comparative interventional trial of patients undergoing cataract surgery. All patients received a single injection of subconjunctival LPP intraoperatively. The primary outcome measure was the proportion of eyes with an anterior chamber cell count of 0 at postoperative month 1. Ocular and non-ocular adverse events, including elevated intraocular pressure, rebound iritis and pseudophakic macular edema were monitored. Five patients were enrolled in this study. The mean age was 66.6 ± 6.2 and 4 (80%) were male. The proportion of patients with AC cell grading of 0 was 0%, 80%, 80%, and 100% at day 1, week 1, month 1, and month 2 after cataract surgery, respectively. Mean laser flare photometry readings were significantly elevated at week 1 after cataract surgery (48.8 ± 18.9, p = 0.03) compared with baseline, decreasing to 25.8 ± 9.2 (p = 0.04) at month 1 and returned to baseline by month 2 (10.9 ± 5.1, p = 1.0). No ocular or non-ocular adverse events were observed. Liposomal prednisolone phosphate, administered as a single subconjunctival injection intraoperatively, can be a safe and effective treatment for post-cataract surgery inflammation. The delivery of steroids with a liposomal drug delivery system could potentially replace eyedrops as anti-inflammatory therapy following cataract surgery.
Collapse
Affiliation(s)
- Chee Wai Wong
- Singapore National Eye Centre (SNEC), 11 Third Hospital Avenue, Singapore City, 168751, Singapore
- Singapore Eye Research Institute, 11 Third Hospital Avenue, Singapore City, 168751, Singapore
- Duke-National University of Singapore Medical School, 8 College Rd, Singapore City, 169857, Singapore
| | - Edmund Wong
- Singapore National Eye Centre (SNEC), 11 Third Hospital Avenue, Singapore City, 168751, Singapore
- Singapore Eye Research Institute, 11 Third Hospital Avenue, Singapore City, 168751, Singapore
- Duke-National University of Singapore Medical School, 8 College Rd, Singapore City, 169857, Singapore
| | - Josbert M Metselaar
- Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, 52074, Aachen, Germany
| | - Gert Storm
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, PO Box 80082, 3508 TB, Utrecht, The Netherlands
| | - Tina T Wong
- Singapore National Eye Centre (SNEC), 11 Third Hospital Avenue, Singapore City, 168751, Singapore.
- Singapore Eye Research Institute, 11 Third Hospital Avenue, Singapore City, 168751, Singapore.
- Duke-National University of Singapore Medical School, 8 College Rd, Singapore City, 169857, Singapore.
| |
Collapse
|
6
|
Roemhild K, Besse HC, Wang B, Peña Q, Sun Q, Omata D, Ozbakir B, Bos C, Scheeren HW, Storm G, Metselaar JM, Yu H, Knüchel-Clarke R, Kiessling F, Moonen CT, Deckers R, Shi Y, Lammers T. Ultrasound-directed enzyme-prodrug therapy (UDEPT) using self-immolative doxorubicin derivatives. Am J Cancer Res 2022; 12:4791-4801. [PMID: 35832083 PMCID: PMC9254251 DOI: 10.7150/thno.69168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2021] [Accepted: 03/22/2022] [Indexed: 11/05/2022] Open
Abstract
Background: Enzyme-activatable prodrugs are extensively employed in oncology and beyond. Because enzyme concentrations and their (sub)cellular compartmentalization are highly heterogeneous in different tumor types and patients, we propose ultrasound-directed enzyme-prodrug therapy (UDEPT) as a means to increase enzyme access and availability for prodrug activation locally. Methods: We synthesized β-glucuronidase-sensitive self-immolative doxorubicin prodrugs with different spacer lengths between the active drug moiety and the capping group. We evaluated drug conversion, uptake and cytotoxicity in the presence and absence of the activating enzyme β-glucuronidase. To trigger the cell release of β-glucuronidase, we used high-intensity focused ultrasound to aid in the conversion of the prodrugs into their active counterparts. Results: More efficient enzymatic activation was observed for self-immolative prodrugs with more than one aromatic unit in the spacer. In the absence of β-glucuronidase, the prodrugs showed significantly reduced cellular uptake and cytotoxicity compared to the parent drug. High-intensity focused ultrasound-induced mechanical destruction of cancer cells resulted in release of intact β-glucuronidase, which activated the prodrugs, restored their cytotoxicity and induced immunogenic cell death. Conclusion: These findings shed new light on prodrug design and activation, and they contribute to novel UDEPT-based mechanochemical combination therapies for the treatment of cancer.
Collapse
|
7
|
Metselaar JM, Middelink LM, Wortel CH, Bos R, van Laar JM, Vonkeman HE, Westhovens R, Lammers T, Yao SL, Kothekar M, Raut A, Bijlsma JWJ. Intravenous pegylated liposomal prednisolone outperforms intramuscular methylprednisolone in treating rheumatoid arthritis flares: A randomized controlled clinical trial. J Control Release 2021; 341:548-554. [PMID: 34896445 DOI: 10.1016/j.jconrel.2021.12.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2021] [Revised: 11/18/2021] [Accepted: 12/05/2021] [Indexed: 11/17/2022]
Abstract
Glucocorticoids (GCs) are potent anti-inflammatory drugs but their use is limited by systemic exposure leading to toxicity. Targeted GC delivery to sites of inflammation via encapsulation in long-circulating liposomes may improve the therapeutic index. We performed a randomized, double-blind, active-controlled, multi-center study in which intravenously (i.v.) administered pegylated liposomal prednisolone sodium phosphate (Nanocort) was compared to equipotent intramuscular (i.m.) methylprednisolone acetate (Depo-Medrol®; i.e. a current standards-of-care for treating flares in rheumatoid arthritis patients). We enrolled 172 patients with active arthritis who met all eligibility criteria, eventually resulting in 150 patients randomized in three groups: (1) Nanocort 75 mg i.v. infusion plus i.m. saline injection; (2) Nanocort 150 mg i.v. infusion plus i.m. saline injection; and (3) Depo-Medrol® 120 mg i.m. injection plus i.v. saline infusion. Dosing in each group occurred at baseline and on day 15 (week 2). Study visits occurred at week 1, 2, 3, 4, 6, 8 and 12, to assess both efficacy and safety. The primary endpoint was the "European League Against Rheumatism" (EULAR) responder rate at week 1. Safety was determined by the occurrence of adverse events during treatment and 12 weeks of follow-up. Treatment with Nanocort was found to be superior to Depo-Medrol® in terms of EULAR response at week 1, with p-values of 0.007 (good response) and 0.018 (moderate response). Treatments were well tolerated with a comparable pattern of adverse events in the three treatment groups. However, the Nanocort groups had a higher incidence of hypersensitivity reactions during liposome infusion. Our results show that liposomal Nanocort is more effective than Depo-Medrol® in treating patients with rheumatoid arthritis flares and has similar safety. This is the first clinical study in a large patient population showing that i.v. administered targeted drug delivery with a nanomedicine formulation improves the therapeutic index of glucocorticoids.
Collapse
Affiliation(s)
- Josbert M Metselaar
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Faculty of Medicine, RWTH Aachen University, Aachen, Germany; Enceladus, Naarden, the Netherlands.
| | | | | | | | - Jacob M van Laar
- Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Harald E Vonkeman
- Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente and University of Twente, Enschede, the Netherlands
| | - Rene Westhovens
- Department of Development and Regeneration, Skeletal Biology and Engineering Research Center and University Hospital KU Leuven, Leuven, Belgium
| | - Twan Lammers
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Faculty of Medicine, RWTH Aachen University, Aachen, Germany
| | - Siu-Long Yao
- Sun Pharmaceutical Industries, Cranbury, NJ, USA
| | | | - Atul Raut
- Sun Pharmaceutical Industries, Mumbai, Maharashtra, India
| | - Johannes W J Bijlsma
- Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands
| |
Collapse
|
8
|
Vrouwe JPM, Kamerling IMC, van Esdonk MJ, Metselaar JM, Stuurman FE, van der Pluijm G, Burggraaf J, Osanto S. An exploratory first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2- and 1-week interval in patients with metastatic castration resistant prostate cancer. Pharmacol Res Perspect 2021; 9:e00845. [PMID: 34414692 PMCID: PMC8377443 DOI: 10.1002/prp2.845] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2021] [Accepted: 05/28/2021] [Indexed: 11/16/2022] Open
Abstract
Dexamethasone has antitumor activity in metastatic castration resistant prostate cancer (mCRPC). We aimed to investigate intravenous liposome-encapsulated dexamethasone disodium phosphate (liposomal dexamethasone) administration in mCRPC patients. In this exploratory first-in-man study, patients in part A received a starting dose of 10 mg followed by five doses of 20 mg liposomal dexamethasone at 2-week intervals. Upon review of part A safety, patients in part B received 10 weekly doses of 18.5 mg. Primary outcomes were safety and pharmacokinetic profile, secondary outcome was antitumor efficacy. Nine mCRPC patients (5 part A, 4 part B) were enrolled. All patients experienced grade 1-2 toxicity, one (part B) patient experienced grade 3 toxicity (permanent bladder catheter-related urosepsis). No infusion-related adverse events occurred. One patient had upsloping glucose levels ≤9.1 mmol/L. Trough plasma concentrations of liposomal- and free dexamethasone were below the lower limit of quantification (LLOQ) in part A, and above LLOQ in three patients in part B (t1/2 ~50 h for liposomal dexamethasone), trough concentrations of liposomal- and free dexamethasone increased toward the end of the study. In seven of nine patients (78%) patients, stable disease was observed in bone and/or CT scans at follow-up, and in one (part B) of these seven patients a >50% PSA biochemical response was observed. Bi- and once weekly administrations of IV liposomal dexamethasone were well-tolerated. Weekly dosing enabled trough concentrations of liposomal- and free dexamethasone >LLOQ. The data presented support further clinical investigation in well-powered studies. Clinical trial registration: ISRCTN 10011715.
Collapse
Affiliation(s)
- Josephina P. M. Vrouwe
- Centre for Human Drug ResearchLeidenThe Netherlands
- Department of Medical OncologyLeiden University Medical CentreLeidenThe Netherlands
| | - Ingrid M. C. Kamerling
- Centre for Human Drug ResearchLeidenThe Netherlands
- Department of Infectious DiseasesLeiden University Medical CentreLeidenThe Netherlands
| | | | - Josbert M. Metselaar
- Enceladus PharmaceuticalsNaardenThe Netherlands
- Rheinisch‐Westfälische Technische Hochschule Aachen University ClinicAachenGermany
| | - Frederik E. Stuurman
- Centre for Human Drug ResearchLeidenThe Netherlands
- Department of Clinical Pharmacology and ToxicologyLeiden University Medical CentreLeidenThe Netherlands
| | | | - Jacobus Burggraaf
- Centre for Human Drug ResearchLeidenThe Netherlands
- Leiden Academic Centre for Drug ResearchLeidenThe Netherlands
| | - Susanne Osanto
- Department of Medical OncologyLeiden University Medical CentreLeidenThe Netherlands
| |
Collapse
|
9
|
van Alem CMA, Metselaar JM, van Kooten C, Rotmans JI. Recent Advances in Liposomal-Based Anti-Inflammatory Therapy. Pharmaceutics 2021; 13:pharmaceutics13071004. [PMID: 34371695 PMCID: PMC8309101 DOI: 10.3390/pharmaceutics13071004] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Revised: 06/27/2021] [Accepted: 06/28/2021] [Indexed: 01/13/2023] Open
Abstract
Liposomes can be seen as ideal carriers for anti-inflammatory drugs as their ability to (passively) target sites of inflammation and release their content to inflammatory target cells enables them to increase local efficacy with only limited systemic exposure and adverse effects. Nonetheless, few liposomal formulations seem to reach the clinic. The current review provides an overview of the more recent innovations in liposomal treatment of rheumatoid arthritis, psoriasis, vascular inflammation, and transplantation. Cutting edge developments include the liposomal delivery of gene and RNA therapeutics and the use of hybrid systems where several liposomal bilayer features, or several drugs, are combined in a single formulation. The majority of the articles reviewed here focus on preclinical animal studies where proof-of-principle of an improved efficacy-safety ratio is observed when using liposomal formulations. A few clinical studies are included as well, which brings us to a discussion about the challenges of clinical translation of liposomal nanomedicines in the field of inflammatory diseases.
Collapse
Affiliation(s)
- Carla M. A. van Alem
- Department of Internal Medicine, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; (C.M.A.v.A.); (C.v.K.)
| | - Josbert M. Metselaar
- Institute for Experimental Molecular Imaging, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany;
| | - Cees van Kooten
- Department of Internal Medicine, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; (C.M.A.v.A.); (C.v.K.)
| | - Joris I. Rotmans
- Department of Internal Medicine, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; (C.M.A.v.A.); (C.v.K.)
- Correspondence: ; Tel.: +31-(0)-7152-62148
| |
Collapse
|
10
|
Affiliation(s)
- Peter Hoogevest
- Phospholipid Research Center Im Neuenheimer Feld 515 Heidelberg 69120D‐69120 Germany
| | - Harry Tiemessen
- Technical & Research Development PHAD PDU Specialty Novartis Campus Physical Garden (WSJ 177) 2.14 Basel CH‐4002 Switzerland
| | - Josbert M. Metselaar
- Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic Aachen D‐52074 Germany
- Institute for Biomedical Engineering, Faculty of Medicine RWTH Aachen University Aachen D‐52074 Germany
| | - Simon Drescher
- Phospholipid Research Center Im Neuenheimer Feld 515 Heidelberg D‐69120 Germany
| | - Alfred Fahr
- Professor Emeritus, Pharmaceutical Technology Friedrich‐Schiller‐University Jena Jena Germany
| |
Collapse
|
11
|
Wong CW, Metselaar JM, Storm G, Wong TT. A review of the clinical applications of drug delivery systems for the treatment of ocular anterior segment inflammation. Br J Ophthalmol 2020; 105:1617-1622. [DOI: 10.1136/bjophthalmol-2020-315911] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2020] [Revised: 09/08/2020] [Accepted: 10/12/2020] [Indexed: 01/14/2023]
Abstract
Ocular anterior segment inflammation is a medical problem that is seen in cases of cataract surgery and non-infectious anterior uveitis. Inadequately treated anterior segment inflammation can lead to sight-threatening conditions such as corneal oedema, glaucoma and cystoid macular oedema. The mainstay of treatment for anterior segment inflammation is topical steroid eye-drops. However, several drawbacks limit the critical value of this treatment, including low bioavailability, poor patient compliance, relatively difficult administration manner and risk of blurring of vision and ocular irritation. A drug delivery system (DDS) that can provide increased bioavailability and sustained delivery while being specifically targeted towards inflamed ocular tissue can potentially replace daily eye-drops as the gold standard for management of anterior segment inflammation. The various DDS for anti-inflammatory drugs for the treatment of anterior segment inflammation are listed and summarised in this review, with a focus on commercially available products and those in clinical trials. Dextenza, INVELTYS, Dexycu and Bromsite are examples of DDS that have enjoyed success in clinical trials leading to FDA approval. Nanoparticles and ocular iontophoresis form the next wave of DDS that have the potential to replace topical steroids eye-drops as the treatment of choice for anterior segment inflammation. With the current relentless pace of ophthalmic drug delivery research, the pursuit of a new standard of treatment that eliminates the problems of low bioavailability and patient compliance may soon be realised.
Collapse
|
12
|
Liang C, Bai X, Qi C, Sun Q, Han X, Lan T, Zhang H, Zheng X, Liang R, Jiao J, Zheng Z, Fang J, Lei P, Wang Y, Möckel D, Metselaar JM, Storm G, Hennink WE, Kiessling F, Wei H, Lammers T, Shi Y, Wei B. Π electron-stabilized polymeric micelles potentiate docetaxel therapy in advanced-stage gastrointestinal cancer. Biomaterials 2020; 266:120432. [PMID: 33069116 DOI: 10.1016/j.biomaterials.2020.120432] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Revised: 09/10/2020] [Accepted: 10/03/2020] [Indexed: 12/12/2022]
Abstract
Gastrointestinal (GI) cancers are among the most lethal malignancies. The treatment of advanced-stage GI cancer involves standard chemotherapeutic drugs, such as docetaxel, as well as targeted therapeutics and immunomodulatory agents, all of which are only moderately effective. We here show that Π electron-stabilized polymeric micelles based on PEG-b-p(HPMAm-Bz) can be loaded highly efficiently with docetaxel (loading capacity up to 23 wt%) and potentiate chemotherapy responses in multiple advanced-stage GI cancer mouse models. Complete cures and full tumor regression were achieved upon intravenously administering micellar docetaxel in subcutaneous gastric cancer cell line-derived xenografts (CDX), as well as in CDX models with intraperitoneal and lung metastases. Nanoformulated docetaxel also outperformed conventional docetaxel in a patient-derived xenograft (PDX) model, doubling the extent of tumor growth inhibition. Furthermore, micellar docetaxel modulated the tumor immune microenvironment in CDX and PDX tumors, increasing the ratio between M1-and M2-like macrophages, and toxicologically, it was found to be very well-tolerated. These findings demonstrate that Π electron-stabilized polymeric micelles loaded with docetaxel hold significant potential for the treatment of advanced-stage GI cancers.
Collapse
Affiliation(s)
- Chenghua Liang
- Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China
| | - Xiangyang Bai
- Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074, Aachen, Germany
| | - Cuiling Qi
- Vascular Biology Research Institute, School of Basic Course, Guangdong Pharmaceutical University, Guangzhou, 510006, China
| | - Qingxue Sun
- Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074, Aachen, Germany
| | - Xiaoyan Han
- Central Laboratory, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China
| | - Tianyun Lan
- Central Laboratory, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China
| | - Haibo Zhang
- Central Laboratory, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China
| | - Xiaoming Zheng
- Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China
| | - Rongpu Liang
- Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China
| | - Ju Jiao
- Department of Nuclear Medicine, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China
| | - Zongheng Zheng
- Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China
| | - Jiafeng Fang
- Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China
| | - Purun Lei
- Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China
| | - Yan Wang
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG, Utrecht, the Netherlands
| | - Diana Möckel
- Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074, Aachen, Germany
| | - Josbert M Metselaar
- Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074, Aachen, Germany
| | - Gert Storm
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG, Utrecht, the Netherlands; Department of Biomaterials Science & Technology (BST), University of Twente, 7500 AE, Enschede, the Netherlands
| | - Wim E Hennink
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG, Utrecht, the Netherlands
| | - Fabian Kiessling
- Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074, Aachen, Germany; Fraunhofer MEVIS, Institute for Medical Image Computing, 52074, Aachen, Germany
| | - Hongbo Wei
- Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China.
| | - Twan Lammers
- Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074, Aachen, Germany; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG, Utrecht, the Netherlands; Department of Biomaterials Science & Technology (BST), University of Twente, 7500 AE, Enschede, the Netherlands.
| | - Yang Shi
- Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074, Aachen, Germany.
| | - Bo Wei
- Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China.
| |
Collapse
|
13
|
Lammers T, Sofias AM, van der Meel R, Schiffelers R, Storm G, Tacke F, Koschmieder S, Brümmendorf TH, Kiessling F, Metselaar JM. Dexamethasone nanomedicines for COVID-19. Nat Nanotechnol 2020; 15:622-624. [PMID: 32747742 PMCID: PMC7116110 DOI: 10.1038/s41565-020-0752-z] [Citation(s) in RCA: 113] [Impact Index Per Article: 28.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/18/2023]
Affiliation(s)
- Twan Lammers
- Institute for Experimental Molecular Imaging, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
- Department of Pharmaceutics, Utrecht University, Utrecht, The Netherlands.
- Department of Targeted Therapeutics, University of Twente, Enschede, The Netherlands.
| | - Alexandros Marios Sofias
- Institute for Experimental Molecular Imaging, Faculty of Medicine, RWTH Aachen University, Aachen, Germany
| | - Roy van der Meel
- Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, The Netherlands
| | - Raymond Schiffelers
- Department of Pharmaceutics, Utrecht University, Utrecht, The Netherlands
- Laboratory of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Gert Storm
- Department of Pharmaceutics, Utrecht University, Utrecht, The Netherlands
- Department of Targeted Therapeutics, University of Twente, Enschede, The Netherlands
- Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore
| | - Frank Tacke
- Department of Hepatology and Gastroenterology, Charité University Medicine, Berlin, Germany
| | - Steffen Koschmieder
- Department of Medicine IV (Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation), RWTH Aachen University, Aachen, Germany
| | - Tim H Brümmendorf
- Department of Medicine IV (Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation), RWTH Aachen University, Aachen, Germany
| | - Fabian Kiessling
- Institute for Experimental Molecular Imaging, Faculty of Medicine, RWTH Aachen University, Aachen, Germany
| | - Josbert M Metselaar
- Institute for Experimental Molecular Imaging, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
| |
Collapse
|
14
|
Besse HC, Chen Y, Scheeren HW, Metselaar JM, Lammers T, Moonen CTW, Hennink WE, Deckers R. A Doxorubicin-Glucuronide Prodrug Released from Nanogels Activated by High-Intensity Focused Ultrasound Liberated β-Glucuronidase. Pharmaceutics 2020; 12:E536. [PMID: 32532061 PMCID: PMC7355552 DOI: 10.3390/pharmaceutics12060536] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Revised: 06/05/2020] [Accepted: 06/09/2020] [Indexed: 11/16/2022] Open
Abstract
The poor pharmacokinetics and selectivity of low-molecular-weight anticancer drugs contribute to the relatively low effectiveness of chemotherapy treatments. To improve the pharmacokinetics and selectivity of these treatments, the combination of a doxorubicin-glucuronide prodrug (DOX-propGA3) nanogel formulation and the liberation of endogenous β-glucuronidase from cells exposed to high-intensity focused ultrasound (HIFU) were investigated in vitro. First, a DOX-propGA3-polymer was synthesized. Subsequently, DOX-propGA3-nanogels were formed from this polymer dissolved in water using inverse mini-emulsion photopolymerization. In the presence of bovine β-glucuronidase, the DOX-propGA3 in the nanogels was quantitatively converted into the chemotherapeutic drug doxorubicin. Exposure of cells to HIFU efficiently induced liberation of endogenous β-glucuronidase, which in turn converted the prodrug released from the DOX-propGA3-nanogels into doxorubicin. β-glucuronidase liberated from cells exposed to HIFU increased the cytotoxicity of DOX-propGA3-nanogels to a similar extend as bovine β-glucuronidase, whereas in the absence of either bovine β-glucuronidase or β-glucuronidase liberated from cells exposed to HIFU, the DOX-propGA3-nanogels hardly showed cytotoxicity. Overall, DOX-propGA3-nanogels systems might help to further improve the outcome of HIFU-related anticancer therapy.
Collapse
Affiliation(s)
- Helena C. Besse
- Division of Imaging and Oncology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands; (H.C.B.); (C.T.W.M.)
| | - Yinan Chen
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands; (Y.C.); (T.L.); (W.E.H.)
| | - Hans W. Scheeren
- Cluster for Molecular Chemistry, Radboud University, 6525 XZ Nijmegen, The Netherlands;
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, 52074 Aachen, Germany;
| | - Josbert M. Metselaar
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, 52074 Aachen, Germany;
- Department of Targeted Therapeutics, MIRA Institute for Biomedical Engineering and Technical Medicine, University of Twente, 7500 AE Enschede, The Netherlands
| | - Twan Lammers
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands; (Y.C.); (T.L.); (W.E.H.)
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, 52074 Aachen, Germany;
- Department of Targeted Therapeutics, MIRA Institute for Biomedical Engineering and Technical Medicine, University of Twente, 7500 AE Enschede, The Netherlands
| | - Chrit T. W. Moonen
- Division of Imaging and Oncology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands; (H.C.B.); (C.T.W.M.)
| | - Wim E. Hennink
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands; (Y.C.); (T.L.); (W.E.H.)
| | - Roel Deckers
- Division of Imaging and Oncology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands; (H.C.B.); (C.T.W.M.)
| |
Collapse
|
15
|
Voorzaat BM, van der Bogt KEA, Bezhaeva T, van Schaik J, Eefting D, van der Putten K, van Nieuwenhuizen RC, Groeneveld JO, Hoogeveen EK, van der Meer IM, Statius van Eps RG, Vogt L, Huisman L, Gabreëls BATF, Boom H, Verburgh CA, Boon D, Metselaar JM, Weijmer MC, Rotmans JI. A Randomized Trial of Liposomal Prednisolone (LIPMAT) to Enhance Radiocephalic Fistula Maturation: A Pilot Study. Kidney Int Rep 2020; 5:1327-1332. [PMID: 32775836 PMCID: PMC7403542 DOI: 10.1016/j.ekir.2020.05.030] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2020] [Revised: 05/21/2020] [Accepted: 05/29/2020] [Indexed: 11/28/2022] Open
Affiliation(s)
- Bram M Voorzaat
- Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - K E A van der Bogt
- Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.,Department of Vascular Surgery, Haaglanden Medical Center, The Hague, The Netherlands
| | - Taisiya Bezhaeva
- Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Jan van Schaik
- Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
| | - Daniel Eefting
- Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.,Department of Vascular Surgery, Haaglanden Medical Center, The Hague, The Netherlands
| | | | | | | | - Ellen K Hoogeveen
- Department of Nephrology, Jeroen Bosch Ziekenhuis, Hertogenbosch, The Netherlands
| | | | | | - Liffert Vogt
- Department of Nephrology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Laurens Huisman
- Department of Vascular Surgery, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | | | - Henk Boom
- Department of Nephrology, Reinier de Graaf Hospital, Delft, The Netherlands
| | | | - Diederik Boon
- Department of Nephrology, Dijklander Hospital, Hoorn, The Netherlands
| | - Josbert M Metselaar
- Management Team, Enceladus Pharmaceuticals, Naarden, The Netherlands.,Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, Aachen, Germany
| | | | - Joris I Rotmans
- Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands
| |
Collapse
|
16
|
Sheybanifard M, Beztsinna N, Bagheri M, Buhl EM, Bresseleers J, Varela-Moreira A, Shi Y, van Nostrum CF, van der Pluijm G, Storm G, Hennink WE, Lammers T, Metselaar JM. Systematic evaluation of design features enables efficient selection of Π electron-stabilized polymeric micelles. Int J Pharm 2020; 584:119409. [PMID: 32389790 DOI: 10.1016/j.ijpharm.2020.119409] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2020] [Revised: 05/03/2020] [Accepted: 05/04/2020] [Indexed: 11/26/2022]
Abstract
Polymeric micelles (PM) based on poly(ethylene glycol)-b-poly(N-2-benzoyloxypropyl methacrylamide) (mPEG-b-p(HPMA-Bz)) loaded with paclitaxel (PTX-PM) have shown promising results in overcoming the suboptimal efficacy/toxicity profile of paclitaxel. To get insight into the stability of PTX-PM formulations upon storage and to optimize their in vivo tumor-targeted drug delivery properties, we set out to identify a lead PTX-PM formulation with the optimal polymer composition. To this end, PM based on four different mPEG5k-b-p(HPMA-Bz) block copolymers with varying molecular weight of the hydrophobic block (17-3 kDa) were loaded with different amounts of PTX. The hydrodynamic diameter was 52 ± 1 nm for PM prepared using polymers with longer hydrophobic blocks (mPEG5k-b-p(HPMA-Bz)17k and mPEG5k-b-p(HPMA-Bz)10k) and 39 ± 1 nm for PM composed of polymers with shorter hydrophobic blocks (mPEG5k-b-p(HPMA-Bz)5k and mPEG5k-b-p(HPMA-Bz)3k). The best storage stability and the slowest PTX release was observed for PM with larger hydrophobic blocks. On the other hand, smaller sized PM of shorter mPEG5k-b-p(HPMA-Bz)5k showed a better tumor penetration in 3D spheroids. Considering better drug retention capacity of the mPEG5k-b-p(HPMA-Bz)17k and smaller size of the mPEG5k-b-p(HPMA-Bz)5k as two desirable design features, we argue that PM based on these two polymers are the lead candidates for further in vivo studies.
Collapse
Affiliation(s)
- Maryam Sheybanifard
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany
| | - Nataliia Beztsinna
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, 3508 TB Utrecht, the Netherlands
| | - Mahsa Bagheri
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, 3508 TB Utrecht, the Netherlands
| | - Eva Miriam Buhl
- Electron Microscopy Facility, Institute of Pathology, RWTH University Hospital, Aachen, Germany
| | - Jaleesa Bresseleers
- ChemConnection BV - Ardena Oss, 5349 AB Oss, the Netherlands; Department of Bio-Organic Chemistry, Eindhoven University of Technology, 5600 MB Eindhoven, the Netherlands
| | - Aida Varela-Moreira
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, 3508 TB Utrecht, the Netherlands; Laboratory of Clinical Chemistry and Hematology (LKCH), University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands
| | - Yang Shi
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany
| | - Cornelus F van Nostrum
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, 3508 TB Utrecht, the Netherlands
| | - Gabri van der Pluijm
- Leiden University Medical Center, Department of Urology, J-3-108, Albinusdreef 2, 2333 ZA Leiden, the Netherlands
| | - Gert Storm
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, 3508 TB Utrecht, the Netherlands; Department of Biomaterials Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, the Netherlands
| | - Wim E Hennink
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, 3508 TB Utrecht, the Netherlands
| | - Twan Lammers
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, 3508 TB Utrecht, the Netherlands; Department of Biomaterials Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, the Netherlands
| | - Josbert M Metselaar
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany; Department of Biomaterials Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, the Netherlands.
| |
Collapse
|
17
|
Bresseleers J, Bagheri M, Storm G, Metselaar JM, Hennink WE, Meeuwissen SA, van Hest JCM. Scale-Up of the Manufacturing Process To Produce Docetaxel-Loaded mPEG- b-p(HPMA-Bz) Block Copolymer Micelles for Pharmaceutical Applications. Org Process Res Dev 2019; 23:2707-2715. [PMID: 32952390 PMCID: PMC7493301 DOI: 10.1021/acs.oprd.9b00387] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2019] [Indexed: 12/22/2022]
Abstract
![]()
An
efficient, scalable, and good manufacturing practice (GMP) compatible
process was developed for the production of docetaxel-loaded poly(ethylene
glycol)-b-poly(N-2-benzoyloxypropyl
methacrylamide) (mPEG-b-p(HPMA-Bz)) micelles. First,
the synthesis of the mPEG-b-p(HPMA-Bz) block copolymer
was optimized through step-by-step investigation of the batch synthesis
procedures. This resulted in the production of 1 kg of mPEG-b-p(HPMA-Bz) block copolymer with a 5 kDa PEG block and
an overall molecular weight of 22.5 kDa. Second, the reproducibility
and scalability of micelle formation was investigated for both batch
and continuous flow setups by assessing critical process parameters.
This resulted in the development of a new and highly efficient continuous
flow process, which led to the production of 100 mL of unloaded micelles
with a size of 55 nm. Finally, the loading of the micelles with the
anticancer drug docetaxel was successfully fine-tuned to obtain precise
control on the loaded micelle characteristics. As a result, 100 mL
of docetaxel-loaded micelles (20 mg/mL polymer and 5 mg/mL docetaxel
in the feed) with a size of 55 nm, an encapsulation efficiency of
65%, a loading capacity of 14%, and stable for at least 2 months in
water at room temperature were produced with the newly developed continuous
flow process. In conclusion, this study paves the way for efficient
and robust large-scale production of docetaxel-loaded micelles with
high encapsulation efficiencies and stability, which is crucial for
their applicability as a clinically relevant drug delivery platform.
Collapse
Affiliation(s)
- Jaleesa Bresseleers
- ChemConnection BV - Ardena Oss, 5349 AB Oss, The Netherlands.,Department of Bio-Organic chemistry, Eindhoven University of Technology, 5600 MB Eindhoven, The Netherlands
| | - Mahsa Bagheri
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, 3508 TB Utrecht, The Netherlands
| | - Gert Storm
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, 3508 TB Utrecht, The Netherlands.,Section - Targeted Therapeutics, Department of Biomaterials Science and Technology, Faculty of Science and Technology, University of Twente, 7522 NB Enschede, The Netherlands
| | - Josbert M Metselaar
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging RWTH University Clinic, 52074 Aachen, Germany
| | - Wim E Hennink
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, 3508 TB Utrecht, The Netherlands
| | | | - Jan C M van Hest
- Department of Bio-Organic chemistry, Eindhoven University of Technology, 5600 MB Eindhoven, The Netherlands
| |
Collapse
|
18
|
Cicha I, Chauvierre C, Texier I, Cabella C, Metselaar JM, Szebeni J, Dézsi L, Alexiou C, Rouzet F, Storm G, Stroes E, Bruce D, MacRitchie N, Maffia P, Letourneur D. From design to the clinic: practical guidelines for translating cardiovascular nanomedicine. Cardiovasc Res 2019; 114:1714-1727. [PMID: 30165574 DOI: 10.1093/cvr/cvy219] [Citation(s) in RCA: 52] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/14/2018] [Accepted: 08/23/2018] [Indexed: 12/20/2022] Open
Abstract
Cardiovascular diseases (CVD) account for nearly half of all deaths in Europe and almost 30% of global deaths. Despite the improved clinical management, cardiovascular mortality is predicted to rise in the next decades due to the increasing impact of aging, obesity, and diabetes. The goal of emerging cardiovascular nanomedicine is to reduce the burden of CVD using nanoscale medical products and devices. However, the development of novel multicomponent nano-sized products poses multiple technical, ethical, and regulatory challenges, which often obstruct their road to successful approval and use in clinical practice. This review discusses the rational design of nanoparticles, including safety considerations and regulatory issues, and highlights the steps needed to achieve efficient clinical translation of promising nanomedicinal products for cardiovascular applications.
Collapse
Affiliation(s)
- Iwona Cicha
- Cardiovascular Nanomedicine Unit, Section of Experimental Oncology und Nanomedicine (SEON), ENT-Department, University Hospital Erlangen, Glückstr. 10a, Erlangen, Germany
| | - Cédric Chauvierre
- INSERM U1148, LVTS, Paris Diderot University, Paris 13 University, X. Bichat Hospital, 46 rue H. Huchard, Paris, France
| | | | - Claudia Cabella
- Centro Ricerche Bracco, Bracco Imaging Spa, Colleretto Giacosa, Italy
| | - Josbert M Metselaar
- Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Aachen, Germany
| | - János Szebeni
- Nanomedicine Research and Education Center, Department of Pathophysiology, Semmelweis University, Budapest, Hungary
| | - László Dézsi
- Nanomedicine Research and Education Center, Department of Pathophysiology, Semmelweis University, Budapest, Hungary
| | - Christoph Alexiou
- Cardiovascular Nanomedicine Unit, Section of Experimental Oncology und Nanomedicine (SEON), ENT-Department, University Hospital Erlangen, Glückstr. 10a, Erlangen, Germany
| | - François Rouzet
- INSERM U1148, LVTS, Paris Diderot University, Paris 13 University, X. Bichat Hospital, 46 rue H. Huchard, Paris, France.,Department of Nuclear Medicine, X. Bichat Hospital, Paris, France
| | - Gert Storm
- Department of Pharmaceutics, University of Utrecht, Utrecht, The Netherlands.,Department of Biomaterials Science and Technology, University of Twente, Enschede, The Netherlands
| | - Erik Stroes
- Department of Vascular Medicine, Amsterdam Medical Center, Amsterdam, The Netherlands
| | | | - Neil MacRitchie
- Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
| | - Pasquale Maffia
- Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.,Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.,Department of Pharmacy, University of Naples Federico II, Naples, Italy
| | - Didier Letourneur
- INSERM U1148, LVTS, Paris Diderot University, Paris 13 University, X. Bichat Hospital, 46 rue H. Huchard, Paris, France
| |
Collapse
|
19
|
Kuninty PR, Bansal R, De Geus SWL, Mardhian DF, Schnittert J, van Baarlen J, Storm G, Bijlsma MF, van Laarhoven HW, Metselaar JM, Kuppen PJK, Vahrmeijer AL, Östman A, Sier CFM, Prakash J. ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer. Sci Adv 2019; 5:eaax2770. [PMID: 31517053 PMCID: PMC6726450 DOI: 10.1126/sciadv.aax2770] [Citation(s) in RCA: 74] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/08/2019] [Accepted: 08/05/2019] [Indexed: 05/08/2023]
Abstract
Abundant desmoplastic stroma is the hallmark for pancreatic ductal adenocarcinoma (PDAC), which not only aggravates the tumor growth but also prevents tumor penetration of chemotherapy, leading to treatment failure. There is an unmet clinical need to develop therapeutic solutions to the tumor penetration problem. In this study, we investigated the therapeutic potential of integrin α5 (ITGA5) receptor in the PDAC stroma. ITGA5 was overexpressed in the tumor stroma from PDAC patient samples, and overexpression was inversely correlated with overall survival. In vitro, knockdown of ITGA5 inhibited differentiation of human pancreatic stellate cells (hPSCs) and reduced desmoplasia in vivo. Our novel peptidomimetic AV3 against ITGA5 inhibited hPSC activation and enhanced the antitumor effect of gemcitabine in a 3D heterospheroid model. In vivo, AV3 showed a strong reduction of desmoplasia, leading to decompression of blood vasculature, enhanced tumor perfusion, and thereby the efficacy of gemcitabine in co-injection and patient-derived xenograft tumor models.
Collapse
Affiliation(s)
- Praneeth R. Kuninty
- Department of Biomaterials, Science and Technology, Section: Targeted Therapeutics, Faculty of Science and Technology, University of Twente, Enschede, Netherlands
| | - Ruchi Bansal
- Department of Biomaterials, Science and Technology, Section: Targeted Therapeutics, Faculty of Science and Technology, University of Twente, Enschede, Netherlands
| | | | - Deby F. Mardhian
- Department of Biomaterials, Science and Technology, Section: Targeted Therapeutics, Faculty of Science and Technology, University of Twente, Enschede, Netherlands
| | - Jonas Schnittert
- Department of Biomaterials, Science and Technology, Section: Targeted Therapeutics, Faculty of Science and Technology, University of Twente, Enschede, Netherlands
| | - Joop van Baarlen
- Laboratory Pathology Oost Netherlands (LabPON), Hengelo, Netherlands
| | - Gert Storm
- Department of Biomaterials, Science and Technology, Section: Targeted Therapeutics, Faculty of Science and Technology, University of Twente, Enschede, Netherlands
- Department of Pharmaceutics, Utrecht University, Utrecht, Netherlands
| | - Maarten F. Bijlsma
- Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, Netherlands
| | | | - Josbert M. Metselaar
- ScarTec Therapeutics BV, Enschede, Netherlands
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, RWTH University Clinic, Forckenbeckstrasse 55, 52074 Aachen, Germany
| | - Peter J. K. Kuppen
- Department of Surgery, Leiden University Medical Center, Leiden, Netherlands
| | | | - Arne Östman
- Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden
| | - Cornelis F. M. Sier
- Department of Surgery, Leiden University Medical Center, Leiden, Netherlands
| | - Jai Prakash
- Department of Biomaterials, Science and Technology, Section: Targeted Therapeutics, Faculty of Science and Technology, University of Twente, Enschede, Netherlands
- ScarTec Therapeutics BV, Enschede, Netherlands
- Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden
- Corresponding author.
| |
Collapse
|
20
|
Deshantri AK, Fens MH, Ruiter RWJ, Metselaar JM, Storm G, van Bloois L, Varela-Moreira A, Mandhane SN, Mutis T, Martens ACM, Groen RWJ, Schiffelers RM. Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma. J Control Release 2019; 296:232-240. [PMID: 30682443 DOI: 10.1016/j.jconrel.2019.01.028] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2018] [Revised: 01/08/2019] [Accepted: 01/19/2019] [Indexed: 02/08/2023]
Abstract
Glucocorticoids are the cornerstone in the clinic for treatment of hematological malignancies, including multiple myeloma. Nevertheless, poor pharmacokinetic properties of glucocorticoids require high and frequent dosing with the off-target adverse effects defining the maximum dose. Recently, nanomedicine formulations of glucocorticoids have been developed that improve the pharmacokinetic profile, limit adverse effects and improve solid tumor accumulation. Multiple myeloma is a hematological malignancy characterized by uncontrolled growth of plasma cells. These tumors initiate increased angiogenesis and microvessel density in the bone marrow, which might be exploited using nanomedicines, such as liposomes. Nano-sized particles can accumulate as a result of the increased vascular leakiness at the bone marrow tumor lesions. Pre-clinical screening of novel anti-myeloma therapeutics in vivo requires a suitable animal model that represents key features of the disease. In this study, we show that fluorescently labeled long circulating liposomes were found in plasma up to 24 h after injection in an advanced human-mouse hybrid model of multiple myeloma. Besides the organs involved in clearance, liposomes were also found to accumulate in tumor bearing human-bone scaffolds. The therapeutic efficacy of liposomal dexamethasone phosphate was evaluated in this model showing strong tumor growth inhibition while free drug being ineffective at an equivalent dose (4 mg/kg) regimen. The liposomal formulation slightly reduced total body weight of myeloma-bearing mice during the course of treatment, which appeared reversible when treatment was stopped. Liposomal dexamethasone could be further developed as monotherapy or could fit in with existing therapy regimens to improve therapeutic outcomes for multiple myeloma.
Collapse
Affiliation(s)
- Anil K Deshantri
- Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands; Biological Research Pharmacology Department, Sun Pharma Advanced Research Company Ltd., Vadodara, India
| | - Marcel H Fens
- Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
| | - Ruud W J Ruiter
- Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands
| | - Josbert M Metselaar
- Enceladus Pharmaceuticals, Naarden, The Netherlands; Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Aachen, Germany
| | - Gert Storm
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; Department of Biomaterials Science and Technology, University of Twente, Enschede, The Netherlands
| | - Louis van Bloois
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
| | - Aida Varela-Moreira
- Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
| | - Sanjay N Mandhane
- Biological Research Pharmacology Department, Sun Pharma Advanced Research Company Ltd., Vadodara, India
| | - Tuna Mutis
- Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands
| | - Anton C M Martens
- Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands
| | - Richard W J Groen
- Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands
| | - Raymond M Schiffelers
- Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
| |
Collapse
|
21
|
Bagheri M, Bresseleers J, Varela-Moreira A, Sandre O, Meeuwissen SA, Schiffelers RM, Metselaar JM, van Nostrum CF, van Hest JCM, Hennink WE. Effect of Formulation and Processing Parameters on the Size of mPEG- b-p(HPMA-Bz) Polymeric Micelles. Langmuir 2018; 34:15495-15506. [PMID: 30415546 PMCID: PMC6333397 DOI: 10.1021/acs.langmuir.8b03576] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/23/2018] [Indexed: 06/09/2023]
Abstract
Micelles composed of block copolymers of poly(ethylene glycol)- b-poly( N-2-benzoyloxypropyl methacrylamide) (mPEG- b-p(HPMA-Bz)) have shown great promise as drug-delivery carriers due to their excellent stability and high loading capacity. In the present study, parameters influencing micelle size were investigated to tailor sizes in the range of 25-100 nm. Micelles were prepared by a nanoprecipitation method, and their size was modulated by the block copolymer properties such as molecular weight, their hydrophilic-to-hydrophobic ratio, homopolymer content, as well as formulation and processing parameters. It was shown that the micelles have a core-shell structure using a combination of dynamic light scattering and transmission electron microscopy analysis. By varying the degree of polymerization of the hydrophobic block ( NB) between 68 and 10, at a fixed hydrophilic block mPEG5k ( NA = 114), it was shown that the hydrophobic core of the micelle was collapsed following the power law of ( NB × Nagg)1/3. Further, the calculated brush height was similar for all the micelles examined (10 nm), indicating that crew-cut micelles were made. Both addition of homopolymer and preparation of micelles at lower concentrations or lower rates of addition of the organic solvent to the aqueous phase increased the size of micelles due to partitioning of the hydrophobic homopolymer chains to the core of the micelles and lower nucleation rates, respectively. Furthermore, it was shown that by using different solvents, the size of the micelles substantially changed. The use of acetone, acetonitrile, ethanol, tetrahydrofuran, and dioxane resulted in micelles in the size range of 45-60 nm after removal of the organic solvents. The use of dimethylformamide and dimethylsulfoxide led to markedly larger sizes of 75 and 180 nm, respectively. In conclusion, the results show that by modulating polymer properties and processing conditions, micelles with tailorable sizes can be obtained.
Collapse
Affiliation(s)
- Mahsa Bagheri
- Department
of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS),
Faculty of Science, Utrecht University, 3508 TB Utrecht, The Netherlands
| | - Jaleesa Bresseleers
- ChemConnection
BV, 5349 AB Oss, The Netherlands
- Department
of Bio-Organic Chemistry, Eindhoven University
of Technology, 5600 MB Eindhoven, The Netherlands
| | - Aida Varela-Moreira
- Department
of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS),
Faculty of Science, Utrecht University, 3508 TB Utrecht, The Netherlands
- Department
of Clinical Chemistry and Haematology, University
Medical Centre Utrecht, 3584 CX Utrecht, The Netherlands
| | - Olivier Sandre
- Laboratoire
de Chimie de Polymères Organiques, Université de Bordeaux, UMR 5629 CNRS, 33607 Pessac, France
| | | | - Raymond M. Schiffelers
- Department
of Clinical Chemistry and Haematology, University
Medical Centre Utrecht, 3584 CX Utrecht, The Netherlands
| | - Josbert M. Metselaar
- Department
of Nanomedicine and Theranostics, Institute
for Experimental Molecular Imaging RWTH University Clinic, 52074 Aachen, Germany
| | - Cornelus F. van Nostrum
- Department
of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS),
Faculty of Science, Utrecht University, 3508 TB Utrecht, The Netherlands
| | - Jan C. M. van Hest
- Department
of Bio-Organic Chemistry, Eindhoven University
of Technology, 5600 MB Eindhoven, The Netherlands
| | - Wim E. Hennink
- Department
of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS),
Faculty of Science, Utrecht University, 3508 TB Utrecht, The Netherlands
| |
Collapse
|
22
|
Matuszak J, Dörfler P, Lyer S, Unterweger H, Juenet M, Chauvierre C, Alaarg A, Franke D, Almer G, Texier I, Metselaar JM, Prassl R, Alexiou C, Mangge H, Letourneur D, Cicha I. Comparative analysis of nanosystems’ effects on human endothelial and monocytic cell functions. Nanotoxicology 2018; 12:957-974. [DOI: 10.1080/17435390.2018.1502375] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Jasmin Matuszak
- Section of Experimental Oncology and Nanomedicine (SEON), ENT Department, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
| | - Philipp Dörfler
- Section of Experimental Oncology and Nanomedicine (SEON), ENT Department, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
| | - Stefan Lyer
- Section of Experimental Oncology and Nanomedicine (SEON), ENT Department, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
| | - Harald Unterweger
- Section of Experimental Oncology and Nanomedicine (SEON), ENT Department, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
| | - Maya Juenet
- INSERM, U1148, LVTS, Paris Diderot University, X Bichat Hospital, Paris, France
| | - Cédric Chauvierre
- INSERM, U1148, LVTS, Paris Diderot University, X Bichat Hospital, Paris, France
| | - Amr Alaarg
- Department of Biomaterials Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands
| | | | - Gunter Almer
- Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
| | - Isabelle Texier
- Grenoble Alpes Université, CEA-LETI MINATEC Campus, Grenoble, France
| | - Josbert M. Metselaar
- Department of Biomaterials Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands
- Department of Experimental Molecular Imaging, RWTH University Clinic Aachen, Aachen, Germany
| | - Ruth Prassl
- Institute of Biophysics, Medical University of Graz, Graz, Austria
| | - Christoph Alexiou
- Section of Experimental Oncology and Nanomedicine (SEON), ENT Department, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
| | - Harald Mangge
- Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
| | - Didier Letourneur
- INSERM, U1148, LVTS, Paris Diderot University, X Bichat Hospital, Paris, France
| | - Iwona Cicha
- Section of Experimental Oncology and Nanomedicine (SEON), ENT Department, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
| |
Collapse
|
23
|
Hua S, de Matos MBC, Metselaar JM, Storm G. Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization. Front Pharmacol 2018; 9:790. [PMID: 30065653 PMCID: PMC6056679 DOI: 10.3389/fphar.2018.00790] [Citation(s) in RCA: 442] [Impact Index Per Article: 73.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2018] [Accepted: 06/28/2018] [Indexed: 01/02/2023] Open
Abstract
The use of nanotechnology in medicine has the potential to have a major impact on human health for the prevention, diagnosis, and treatment of diseases. One particular aspect of the nanomedicine field which has received a great deal of attention is the design and development of nanoparticulate nanomedicines (NNMs) for drug delivery (i.e., drug-containing nanoparticles). NNMs are intended to deliver drugs via various mechanisms: solubilization, passive targeting, active targeting, and triggered release. The NNM approach aims to increase therapeutic efficacy, decrease the therapeutically effective dose, and/or reduce the risk of systemic side effects. In order to move a NNM from the bench to the bedside, several experimental challenges need to be addressed. This review will discuss the current trends and challenges in the clinical translation of NNMs as well as the potential pathways for translational development and commercialization. Key issues related to the clinical development of NNMs will be covered, including biological challenges, large-scale manufacturing, biocompatibility and safety, intellectual property (IP), government regulations, and overall cost-effectiveness in comparison to current therapies. These factors can impose significant hurdles limiting the appearance of NNMs on the market, irrelevant of whether they are therapeutically beneficial or not.
Collapse
Affiliation(s)
- Susan Hua
- Therapeutic Targeting Research Group, School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia.,Hunter Medical Research Institute, New Lambton Heights, Newcastle, NSW, Australia
| | - Maria B C de Matos
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands
| | - Josbert M Metselaar
- Department of Biomaterials Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, Netherlands.,Department of Experimental Molecular Imaging, RWTH University Clinic Aachen, Aachen, Germany
| | - Gert Storm
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands.,Department of Biomaterials Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, Netherlands.,Imaging Division, University Medical Centre Utrecht, Utrecht, Netherlands
| |
Collapse
|
24
|
Wong CW, Czarny B, Metselaar JM, Ho C, Ng SR, Barathi AV, Storm G, Wong TT. Evaluation of subconjunctival liposomal steroids for the treatment of experimental uveitis. Sci Rep 2018; 8:6604. [PMID: 29700320 PMCID: PMC5919899 DOI: 10.1038/s41598-018-24545-2] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2017] [Accepted: 03/20/2018] [Indexed: 12/30/2022] Open
Abstract
Non-infectious anterior uveitis (AU) is a potentially sight threatening inflammatory condition. The current gold standard for treatment is topical steroids, but low ocular bioavailability and compliance issues with the intensive dosing regimen limit the efficacy of this treatment. Liposomes as a drug delivery system may help to overcome these problems. We studied the efficacy of a PEG-liposomal formulation of liposomal steroids, administered as a single subconjunctival dose, in the treatment of experimental uveitis in rabbit eyes. Rabbits that received subconjunctival liposomal triamcinolone acetonide phosphate (LTAP) or liposomal prednisolone phosphate (LPP) had significantly lower mean inflammatory scores than untreated controls on Day 4 after induction of uveitis (LPP vs controls, p = 0.049) and 8 (LPP vs controls, p = 0.007; LTAP vs controls, p = 0.019), and lower scores than rabbits given topical PredForte1% 4 times a day on Day 8 (p = 0.03). After antigen rechallenge, the subconjunctival liposomal steroid groups continued to have greater suppression of inflammation than untreated controls on Day 11 (p = 0.02). Localization of liposomes in inflamed ocular tissue was confirmed by histology and immunostaining, and persisted in the eye for at least one month. Our study demonstrates that a single subconjunctival injection of liposomal steroids induces effective and sustained anti-inflammatory action.
Collapse
Affiliation(s)
- Chee Wai Wong
- Singapore National Eye Centre (SNEC), 11 Third Hospital Avenue, Singapore, 168751, Singapore.,Singapore Eye Research Institute, 11 Third Hospital Avenue, Singapore, 168751, Singapore
| | - Bertrand Czarny
- Department Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, PO Box 80082, 3508 TB, Utrecht, The Netherlands.,School of Materials Science and Engineering (MSE), Nanyang Technological University, 11 Faculty Avenue, Singapore, 639977, Singapore.,Lee Kong Chian school of medicine (LKCmedicine), Nanyang Technological University, 11 Mandalay Road, Singapore, 308232, Singapore
| | - Josbert M Metselaar
- Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, 52074, Germany
| | - Candice Ho
- Singapore Eye Research Institute, 11 Third Hospital Avenue, Singapore, 168751, Singapore
| | - Si Rui Ng
- Singapore National Eye Centre (SNEC), 11 Third Hospital Avenue, Singapore, 168751, Singapore.,Singapore Eye Research Institute, 11 Third Hospital Avenue, Singapore, 168751, Singapore
| | | | - Gert Storm
- Department Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, PO Box 80082, 3508 TB, Utrecht, The Netherlands. .,Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, 52074, Germany.
| | - Tina T Wong
- Singapore National Eye Centre (SNEC), 11 Third Hospital Avenue, Singapore, 168751, Singapore. .,Singapore Eye Research Institute, 11 Third Hospital Avenue, Singapore, 168751, Singapore.
| |
Collapse
|
25
|
van der Geest T, Roeleveld DM, Walgreen B, Helsen MM, Nayak TK, Klein C, Hegen M, Storm G, Metselaar JM, van den Berg WB, van der Kraan PM, Laverman P, Boerman OC, Koenders MI. Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis. Rheumatology (Oxford) 2018; 57:737-747. [PMID: 29361119 DOI: 10.1093/rheumatology/kex456] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2017] [Indexed: 12/19/2022] Open
Abstract
Objectives RA is a chronic autoimmune disease leading to progressive destruction of cartilage and bone. RA patients show elevated IL-22 levels and the amount of IL-22-producing Th cells positively correlates with the extent of erosive disease, suggesting a role for this cytokine in RA pathogenesis. The purpose of this study was to determine the feasibility of SPECT/CT imaging with 111In-labelled anti-fibroblast activation protein antibody (28H1) to monitor the therapeutic effect of neutralizing IL-22 in experimental arthritis. Methods Mice (six mice/group) with CIA received anti-IL-22 or isotype control antibodies. To monitor therapeutic effects after treatment, SPECT/CT images were acquired 24 h after injection of 111In-28H1. Imaging results were compared with macroscopic, histologic and radiographic arthritis scores. Results Neutralizing IL-22 before CIA onset effectively prevented arthritis development, reaching a disease incidence of only 50%, vs 100% in the control group. SPECT imaging showed significantly lower joint tracer uptake in mice treated early with anti-IL-22 antibodies compared with the control-treated group. Reduction of disease activity in those mice was confirmed by macroscopic, histological and radiographic pathology scores. However, when treatment was initiated in a later phase of CIA, progression of joint pathology could not be prevented. Conclusion These findings suggest that IL-22 plays an important role in CIA development, and neutralizing this cytokine seems an attractive new strategy in RA treatment. Most importantly, SPECT/CT imaging with 111In-28H1 can be used to specifically monitor therapy responses, and is potentially more sensitive in disease monitoring than the gold standard method of macroscopic arthritis scoring.
Collapse
Affiliation(s)
- Tessa van der Geest
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - Debbie M Roeleveld
- Department of Experimental Rheumatology, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - Birgitte Walgreen
- Department of Experimental Rheumatology, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - Monique M Helsen
- Department of Experimental Rheumatology, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - Tapan K Nayak
- Roche Pharmaceutical Research & Early Development, Innovation Center Basel, Basel, Switzerland
| | - Christian Klein
- Roche Pharmaceutical Research & Early Development, Innovation Center Zurich, Schlieren, Switzerland
| | - Martin Hegen
- Inflammation & Immunology Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, USA
| | - Gert Storm
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht
- Department of Targeted Therapeutics, MIRA Institute, University of Twente, Enschede, The Netherlands
| | - Josbert M Metselaar
- Department of Targeted Therapeutics, MIRA Institute, University of Twente, Enschede, The Netherlands
- Department of Experimental Molecular Imaging, University Clinic & Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Aachen, Germany
| | - Wim B van den Berg
- Department of Experimental Rheumatology, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - Peter M van der Kraan
- Department of Experimental Rheumatology, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - Peter Laverman
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - Otto C Boerman
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands
| | - Marije I Koenders
- Department of Experimental Rheumatology, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands
| |
Collapse
|
26
|
Chen Y, Dakwar GR, Braeckmans K, Lammers T, Hennink WE, Metselaar JM. In Vitro Evaluation of Anti-Aggregation and Degradation Behavior of PEGylated Polymeric Nanogels under In Vivo Like Conditions. Macromol Biosci 2017; 18. [PMID: 29152858 DOI: 10.1002/mabi.201700127] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2017] [Revised: 05/20/2017] [Indexed: 11/07/2022]
Abstract
The in vivo stability and biodegradability of nanocarriers crucially determine therapeutic efficacy as well as safety when used for drug delivery. This study aims to evaluate optimized in vitro techniques predictive for in vivo nanocarrier behavior. Polymeric biodegradable nanogels based on hydroxyethyl methacrylamide-oligoglycolates-derivatized poly(hydroxyethyl methacrylamide-co-N-(2-azidoethyl)methacrylamide) and with various degrees of PEGylation and crosslinking densities are prepared. Three techniques are chosen and refined for specific in vitro evaluation of the nanocarrier performance: (1) fluorescence single particle tracking (fSPT) to study the stability of nanogels in human plasma, (2) tangential flow filtration (TFF) to study the degradation and filtration of nanogel degradation products, and (3) fluorescence fluctuation spectroscopy (FFS) to evaluate and compare the degradation behavior of nanogels in buffer and plasma. fSPT results demonstrate that nanogels with highest PEGylation content show the least aggregation. The TFF results reveal that nanogels with higher crosslink density have slower degradation and removal by filtration. FFS results indicate a similar degradation behavior in human plasma as compared to that in phosphate buffered saline. In conclusion, three methods can be used to compare and select the optimal nanogel composition, and these methods hold potential to predict the in vivo performance of nanocarriers.
Collapse
Affiliation(s)
- Yinan Chen
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584, CG, Utrecht, The Netherlands
| | - George R Dakwar
- Laboratory for General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, 9000, Ghent, Belgium
| | - Kevin Braeckmans
- Laboratory for General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, 9000, Ghent, Belgium
| | - Twan Lammers
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584, CG, Utrecht, The Netherlands.,Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, 52074, Aachen, Germany.,Department of Targeted Therapeutics, MIRA Institute for Biomedical Engineering and Technical Medicine, University of Twente, 7522, NB, Enschede, The Netherlands
| | - Wim E Hennink
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584, CG, Utrecht, The Netherlands
| | - Josbert M Metselaar
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, 52074, Aachen, Germany.,Department of Targeted Therapeutics, MIRA Institute for Biomedical Engineering and Technical Medicine, University of Twente, 7522, NB, Enschede, The Netherlands
| |
Collapse
|
27
|
Chen Y, Tezcan O, Li D, Beztsinna N, Lou B, Etrych T, Ulbrich K, Metselaar JM, Lammers T, Hennink WE. Overcoming multidrug resistance using folate receptor-targeted and pH-responsive polymeric nanogels containing covalently entrapped doxorubicin. Nanoscale 2017; 9:10404-10419. [PMID: 28702658 DOI: 10.1039/c7nr03592f] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
Multidrug resistance (MDR) contributes to failure of chemotherapy. We here show that biodegradable polymeric nanogels are able to overcome MDR via folic acid targeting. The nanogels are based on hydroxyethyl methacrylamide-oligoglycolates-derivatized poly(hydroxyethyl methacrylamide-co-N-(2-azidoethyl)methacrylamide) (p(HEMAm-co-AzEMAm)-Gly-HEMAm), covalently loaded with the chemotherapeutic drug doxorubicin (DOX) and subsequently decorated with a folic acid-PEG conjugate via copper-free click chemistry. pH-Responsive drug release is achieved via the acid-labile hydrazone bond between DOX and the methacrylamide polymeric network. Cellular uptake and cytotoxicity analyses in folate receptor-positive B16F10 melanoma versus folate receptor-negative A549 lung carcinoma cells confirmed specific uptake of the targeted nanogels. Confocal microscopy demonstrated efficient internalization, lysosomal trafficking, drug release and nuclear localization of DOX. We also show that DOX resistance in 4T1 breast cancer cells results in upregulation of the folate receptor, and that folic acid targeted nanogels can be employed to bypass drug efflux pumps, resulting in highly efficient killing of resistant cancer cells. In conclusion, folic acid functionalized nanogels with pH-controlled drug release seem to hold significant potential for treating multidrug resistant malignancies.
Collapse
Affiliation(s)
- Y Chen
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, 3584 CG, The Netherlands.
| | - O Tezcan
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, 52074 Aachen, Germany
| | - D Li
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, 3584 CG, The Netherlands.
| | - N Beztsinna
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, 3584 CG, The Netherlands.
| | - B Lou
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, 3584 CG, The Netherlands.
| | - T Etrych
- Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovsky Square 2, 162 06 Prague 6, Czech Republic
| | - K Ulbrich
- Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovsky Square 2, 162 06 Prague 6, Czech Republic
| | - J M Metselaar
- Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, 52074 Aachen, Germany and Department of Targeted Therapeutics, MIRA Institute for Biomedical Engineering and Technical Medicine, University of Twente, Enschede, 7522 NB, The Netherlands
| | - T Lammers
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, 3584 CG, The Netherlands. and Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic, 52074 Aachen, Germany and Department of Targeted Therapeutics, MIRA Institute for Biomedical Engineering and Technical Medicine, University of Twente, Enschede, 7522 NB, The Netherlands
| | - W E Hennink
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, 3584 CG, The Netherlands.
| |
Collapse
|
28
|
Alaarg A, Senders ML, Varela-Moreira A, Pérez-Medina C, Zhao Y, Tang J, Fay F, Reiner T, Fayad ZA, Hennink WE, Metselaar JM, Mulder WJM, Storm G. A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis. J Control Release 2017; 262:47-57. [PMID: 28700897 DOI: 10.1016/j.jconrel.2017.07.013] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2017] [Revised: 06/27/2017] [Accepted: 07/07/2017] [Indexed: 12/21/2022]
Abstract
Atherosclerosis is a leading cause of worldwide morbidity and mortality whose management could benefit from novel targeted therapeutics. Nanoparticles are emerging as targeted drug delivery systems in chronic inflammatory disorders. To optimally exploit nanomedicines, understanding their biological behavior is crucial for further development of clinically relevant and efficacious nanotherapeutics intended to reduce plaque inflammation. Here, three clinically relevant nanomedicines, i.e., high-density lipoprotein ([S]-HDL), polymeric micelles ([S]-PM), and liposomes ([S]-LIP), that are loaded with the HMG-CoA reductase inhibitor simvastatin [S], were evaluated in the apolipoprotein E-deficient (Apoe-/-) mouse model of atherosclerosis. We systematically employed quantitative techniques, including in vivo positron emission tomography imaging, gamma counting, and flow cytometry to evaluate the biodistribution, nanomedicines' uptake by plaque-associated macrophages/monocytes, and their efficacy to reduce macrophage burden in atherosclerotic plaques. The three formulations demonstrated distinct biological behavior in Apoe-/- mice. While [S]-PM and [S]-LIP possessed longer circulation half-lives, the three platforms accumulated to similar levels in atherosclerotic plaques. Moreover, [S]-HDL and [S]-PM showed higher uptake by plaque macrophages in comparison to [S]-LIP, while [S]-PM demonstrated the highest uptake by Ly6Chigh monocytes. Among the three formulations, [S]-PM displayed the highest efficacy in reducing macrophage burden in advanced atherosclerotic plaques. In conclusion, our data demonstrate that [S]-PM is a promising targeted drug delivery system, which can be advanced for the treatment of atherosclerosis and other inflammatory disorders in the clinical settings. Our results also emphasize the importance of a thorough understanding of nanomedicines' biological performance, ranging from the whole body to the target cells, as well drug retention in the nanoparticles. Such systematic investigations would allow rational applications of nanomaterials', beyond cancer, facilitating the expansion of the nanomedicine horizon.
Collapse
Affiliation(s)
- Amr Alaarg
- Department of Biomaterials Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede 7500 AE, The Netherlands; Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CG, The Netherlands
| | - Max L Senders
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Medical Biochemistry, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
| | - Aida Varela-Moreira
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CG, The Netherlands; Department of Clinical Chemistry and Haematology, University Medical Centre Utrecht, Utrecht 3584 CX, The Netherlands
| | - Carlos Pérez-Medina
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Yiming Zhao
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Jun Tang
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Francois Fay
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Chemistry, York College of The City University of New York, New York, NY 11451, USA
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA
| | - Zahi A Fayad
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Wim E Hennink
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CG, The Netherlands
| | - Josbert M Metselaar
- Department of Biomaterials Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede 7500 AE, The Netherlands; Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen 52074, Germany
| | - Willem J M Mulder
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Medical Biochemistry, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands.
| | - Gert Storm
- Department of Biomaterials Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede 7500 AE, The Netherlands; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CG, The Netherlands; Imaging Division, University Medical Centre Utrecht, Utrecht 3584 CX, The Netherlands.
| |
Collapse
|
29
|
van Alem CMA, Boonstra M, Prins J, Bezhaeva T, van Essen MF, Ruben JM, Vahrmeijer AL, van der Veer EP, de Fijter JW, Reinders ME, Meijer O, Metselaar JM, van Kooten C, Rotmans JI. Local delivery of liposomal prednisolone leads to an anti-inflammatory profile in renal ischaemia–reperfusion injury in the rat. Nephrol Dial Transplant 2017; 33:44-53. [DOI: 10.1093/ndt/gfx204] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2017] [Accepted: 05/03/2017] [Indexed: 02/07/2023] Open
|
30
|
Allijn IE, Czarny BM, Wang X, Chong SY, Weiler M, da Silva AE, Metselaar JM, Lam CSP, Pastorin G, de Kleijn DP, Storm G, Wang JW, Schiffelers RM. Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction. J Control Release 2017; 247:127-133. [DOI: 10.1016/j.jconrel.2016.12.042] [Citation(s) in RCA: 79] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2016] [Accepted: 12/30/2016] [Indexed: 11/27/2022]
|
31
|
Fülöp TG, Metselaar JM, Storm G, Szebeni J. The role of thromboxane A2 in complement activation-related pseudoallergy. European Journal of Nanomedicine 2017. [DOI: 10.1515/ejnm-2016-0039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
AbstractComplement activation-related pseudoallergy (CARPA) is a hypersensitivity reaction occurring upon intravenous administration of numerous liposomal therapeutics, other nonbiological complex drugs and biologicals. It has a complex molecular and cellular mechanism that involves the production, actions and interactions of numerous vasoactive mediators in blood, including thromboxane A
Collapse
|
32
|
Alaarg A, Jordan NY, Verhoef JJ, Metselaar JM, Storm G, Kok RJ. Docosahexaenoic acid liposomes for targeting chronic inflammatory diseases and cancer: an in vitro assessment. Int J Nanomedicine 2016; 11:5027-5040. [PMID: 27785012 PMCID: PMC5063558 DOI: 10.2147/ijn.s115995] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Inflammation, oxidative stress, and uncontrolled cell proliferation are common key features of chronic inflammatory diseases, such as atherosclerosis and cancer. ω3 polyunsaturated fatty acids (PUFAs; also known as omega3 fatty acids or fish oil) have beneficial effects against inflammation upon dietary consumption. However, these effects cannot be fully exploited unless diets are enriched with high concentrations of fish oil supplements over long periods of time. Here, a nanomedicine-based approach is presented for delivering effective levels of PUFAs to inflammatory cells. Nanoparticles are internalized by immune cells, and hence can adequately deliver bioactive lipids into these target cells. The ω3 FA docosahexaenoic acid was formulated into liposomes (ω-liposomes), and evaluated for anti-inflammatory effects in different types of immune cells. ω-Liposomes strongly inhibited the release of reactive oxygen species and reactive nitrogen species from human neutrophils and murine macrophages, and also inhibited the production of the proinflammatory cytokines TNFα and MCP1. Moreover, ω-liposomes inhibited tumor-cell proliferation when evaluated in FaDu head and neck squamous carcinoma and 4T1 breast cancer cells in in vitro cultures. We propose that ω-liposomes are a promising nanonutraceutical formulation for intravenous delivery of fish oil FAs, which may be beneficial in the treatment of inflammatory disorders and cancer.
Collapse
Affiliation(s)
- Amr Alaarg
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht; Department of Biomaterials Science and Technology, Institute for Biomedical Technology and Technical Medicine (MIRA), University of Twente, Enschede, the Netherlands
| | - Nan Yeun Jordan
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht
| | - Johan Jf Verhoef
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht
| | - Josbert M Metselaar
- Department of Biomaterials Science and Technology, Institute for Biomedical Technology and Technical Medicine (MIRA), University of Twente, Enschede, the Netherlands; Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Aachen, Germany
| | - Gert Storm
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht; Department of Biomaterials Science and Technology, Institute for Biomedical Technology and Technical Medicine (MIRA), University of Twente, Enschede, the Netherlands
| | - Robbert J Kok
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht
| |
Collapse
|
33
|
van der Meer LT, Terry SYA, van Ingen Schenau DS, Andree KC, Franssen GM, Roeleveld DM, Metselaar JM, Reinheckel T, Hoogerbrugge PM, Boerman OC, van Leeuwen FN. In Vivo Imaging of Antileukemic Drug Asparaginase Reveals a Rapid Macrophage-Mediated Clearance from the Bone Marrow. J Nucl Med 2016; 58:214-220. [PMID: 27493268 DOI: 10.2967/jnumed.116.177741] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2016] [Accepted: 07/25/2016] [Indexed: 11/16/2022] Open
Abstract
The antileukemic drug asparaginase, a key component in the treatment of acute lymphoblastic leukemia, acts by depleting asparagine from the blood. However, little is known about its pharmacokinetics, and mechanisms of therapy resistance are poorly understood. Here, we explored the in vivo biodistribution of radiolabeled asparaginase, using a combination of imaging and biochemical techniques, and provide evidence for tissue-specific clearance mechanisms, which could reduce the effectiveness of the drug at these specific sites. METHODS In vivo localization of 111In-labeled Escherichia coli asparaginase was performed in C57BL/6 mice by both small-animal SPECT/CT and ex vivo biodistribution studies. Mice were treated with liposomal clodronate to investigate the effect of macrophage depletion on tracer localization and drug clearance in vivo. Moreover, macrophage cell line models RAW264.7 and THP-1, as well as knockout mice, were used to identify the cellular and molecular components controlling asparaginase pharmacokinetics. RESULTS In vivo imaging and biodistribution studies showed a rapid accumulation of asparaginase in macrophage-rich tissues such as the liver, spleen, and in particular bone marrow. Clodronate-mediated depletion of phagocytic cells markedly prolonged the serum half-life of asparaginase in vivo and decreased drug uptake in these macrophage-rich organs. Immunohistochemistry and in vitro binding assays confirmed the involvement of macrophagelike cells in the uptake of asparaginase. We identified the activity of the lysosomal protease cathepsin B in macrophages as a rate-limiting factor in degrading asparaginase both in vitro and in vivo. CONCLUSION We showed that asparaginase is rapidly cleared from the serum by liver-, spleen-, and bone marrow-resident phagocytic cells. As a consequence of this efficient uptake and protease-mediated degradation, particularly bone marrow-resident macrophages may provide a protective niche to leukemic cells.
Collapse
Affiliation(s)
- Laurens T van der Meer
- Laboratory of Pediatric Oncology, Department of Pediatrics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Samantha Y A Terry
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.,Division of Imaging Sciences and Biomedical Engineering, Department of Imaging Chemistry and Biology, King's College London, London, United Kingdom
| | - Dorette S van Ingen Schenau
- Laboratory of Pediatric Oncology, Department of Pediatrics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Kiki C Andree
- Laboratory of Pediatric Oncology, Department of Pediatrics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Gerben M Franssen
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Debbie M Roeleveld
- Laboratory of Pediatric Oncology, Department of Pediatrics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.,Experimental Rheumatology, Radboud Insititute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Josbert M Metselaar
- Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Aachen, Germany
| | - Thomas Reinheckel
- Institute of Molecular Medicine and Cell Research, Albert-Ludwigs-University, Freiburg, Germany.,German Cancer Consortium (DKTK), Freiburg, Germany.,BIOSS Centre for Biological Signalling Studies, Albert-Ludwigs-University, Freiburg, Germany; and
| | | | - Otto C Boerman
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Frank N van Leeuwen
- Laboratory of Pediatric Oncology, Department of Pediatrics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
| |
Collapse
|
34
|
van der Geest T, Laverman P, Gerrits D, Walgreen B, Helsen MM, Klein C, Nayak TK, Storm G, Metselaar JM, Koenders MI, Boerman OC. Liposomal Treatment of Experimental Arthritis Can Be Monitored Noninvasively with a Radiolabeled Anti-Fibroblast Activation Protein Antibody. J Nucl Med 2016; 58:151-155. [PMID: 27493266 DOI: 10.2967/jnumed.116.177931] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2016] [Accepted: 07/13/2016] [Indexed: 11/16/2022] Open
Abstract
Rheumatoid arthritis is a chronic autoimmune disorder resulting in synovial inflammation. Fibroblast activation protein (FAP) is overexpressed by fibroblastlike synoviocytes in arthritic joints. Radioimmunoimaging with an anti-FAP antibody might be used to monitor the response to therapy, thus enabling tailored therapy strategies and therapeutic outcomes. The aim of this study was to assess whether a radiolabeled anti-FAP antibody could be used to monitor the efficacy of treatment with long-circulating liposomes (LCL) containing prednisolone phosphate (PLP-LCL) in a mouse model of arthritis. METHODS Collagen-induced arthritis (CIA) was induced in male DBA/1J mice. Mice were treated with a single injection (10 mg/kg) of PLP-LCL or empty LCL as a control. SPECT and CT images were acquired 24 h after injection of 99mTc-labeled succinimidyl-hydrazinonicotinamide (99mTc-S-HYNIC)-conjugated anti-FAP antibody 28H1 at 2, 5, and 9 d after treatment. The uptake of 99mTc-S-HYNIC-28H1 in all joints was quantified and correlated with macroscopic arthritis scores. RESULTS Treatment of CIA with PLP-LCL significantly suppressed joint swelling. At just 1 d after treatment, the macroscopic arthritis scores had decreased by 50%. Scores decreased further, to only 10% of the initial scores, at 5 and 9 d after treatment. In contrast, macroscopic arthritis scores had increased up to 600% in untreated mice at 9 d after the injection of empty LCL. 99mTc-S-HYNIC-28H1 uptake ranged from 1.5 percentage injected dose per gram in noninflamed joints to 22.6 percentage injected dose per gram in severely inflamed joints. The uptake of radiolabeled 28H1 in inflamed joints (percentage injected dose) correlated with the arthritis score (Spearman ρ, 0.77; P < 0.0001). Moreover, the uptake of 99mTc-S-HYNIC-28H1 was slightly increased at 9 d after therapy but was not seen macroscopically, indicating that SPECT/CT imaging might be more sensitive than the macroscopic arthritis scoring method. CONCLUSION SPECT/CT imaging with 99mTc-S-HYNIC-28H1 specifically monitored the response to therapy, and tracer accumulation correlated with the severity of inflammation. In addition, SPECT/CT imaging was potentially more sensitive than the macroscopic arthritis scoring method. This study showed that SPECT/CT with 99mTc-S-HYNIC-28H1 could be used to noninvasively monitor the course of CIA in mice.
Collapse
Affiliation(s)
- Tessa van der Geest
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Peter Laverman
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Danny Gerrits
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Birgitte Walgreen
- Department of Experimental Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Monique M Helsen
- Department of Experimental Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Christian Klein
- Roche Pharmaceutical Research and Early Development, Innovation Center Zurich, Schlieren, Switzerland
| | - Tapan K Nayak
- Roche Pharmaceutical Research and Early Development, Innovation Center Basel, Basel, Switzerland
| | - Gert Storm
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.,Department of Targeted Therapeutics, MIRA Institute, University of Twente, Zuidhorst, The Netherlands; and
| | - Josbert M Metselaar
- Department of Targeted Therapeutics, MIRA Institute, University of Twente, Zuidhorst, The Netherlands; and.,Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany
| | - Marije I Koenders
- Department of Experimental Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Otto C Boerman
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
| |
Collapse
|
35
|
Chen Y, van Steenbergen MJ, Li D, van de Dikkenberg JB, Lammers T, van Nostrum CF, Metselaar JM, Hennink WE. Macromol. Biosci. 8/2016. Macromol Biosci 2016. [DOI: 10.1002/mabi.201670029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Yinan Chen
- Department of Pharmaceutics; Utrecht Institute for Pharmaceutical Sciences; Utrecht University; 3584 CG Utrecht The Netherlands
| | - Mies J. van Steenbergen
- Department of Pharmaceutics; Utrecht Institute for Pharmaceutical Sciences; Utrecht University; 3584 CG Utrecht The Netherlands
| | - Dandan Li
- Department of Pharmaceutics; Utrecht Institute for Pharmaceutical Sciences; Utrecht University; 3584 CG Utrecht The Netherlands
| | - Joep B. van de Dikkenberg
- Department of Pharmaceutics; Utrecht Institute for Pharmaceutical Sciences; Utrecht University; 3584 CG Utrecht The Netherlands
| | - Twan Lammers
- Department of Pharmaceutics; Utrecht Institute for Pharmaceutical Sciences; Utrecht University; 3584 CG Utrecht The Netherlands
- Department of Targeted Therapeutics; MIRA Institute for Biomedical Engineering and Technical Medicine; University of Twente; 7522 NB Enschede The Netherlands
- Department of Nanomedicine and Theranostics; Institute for Experimental Molecular Imaging; RWTH Aachen University Clinic; 52074 Aachen Germany
| | - Cornelus F. van Nostrum
- Department of Pharmaceutics; Utrecht Institute for Pharmaceutical Sciences; Utrecht University; 3584 CG Utrecht The Netherlands
| | - Josbert M. Metselaar
- Department of Targeted Therapeutics; MIRA Institute for Biomedical Engineering and Technical Medicine; University of Twente; 7522 NB Enschede The Netherlands
- Department of Nanomedicine and Theranostics; Institute for Experimental Molecular Imaging; RWTH Aachen University Clinic; 52074 Aachen Germany
| | - Wim E. Hennink
- Department of Pharmaceutics; Utrecht Institute for Pharmaceutical Sciences; Utrecht University; 3584 CG Utrecht The Netherlands
| |
Collapse
|
36
|
van der Valk FM, Schulte DM, Meiler S, Tang J, Zheng KH, Van den Bossche J, Seijkens T, Laudes M, de Winther M, Lutgens E, Alaarg A, Metselaar JM, Dallinga-Thie GM, Mulder WJ, Stroes ES, Hamers AA. Liposomal prednisolone promotes macrophage lipotoxicity in experimental atherosclerosis. Nanomedicine: Nanotechnology, Biology and Medicine 2016; 12:1463-70. [DOI: 10.1016/j.nano.2016.02.022] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/02/2015] [Revised: 02/17/2016] [Accepted: 02/25/2016] [Indexed: 01/09/2023]
|
37
|
Wong C, Bezhaeva T, Rothuizen TC, Metselaar JM, de Vries MR, Verbeek FPR, Vahrmeijer AL, Wezel A, van Zonneveld AJ, Rabelink TJ, Quax PHA, Rotmans JI. Liposomal prednisolone inhibits vascular inflammation and enhances venous outward remodeling in a murine arteriovenous fistula model. Sci Rep 2016; 6:30439. [PMID: 27460883 PMCID: PMC4962038 DOI: 10.1038/srep30439] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2016] [Accepted: 07/01/2016] [Indexed: 12/20/2022] Open
Abstract
Arteriovenous fistulas (AVF) for hemodialysis access have a 1-year primary patency rate of only 60%, mainly as a result of maturation failure that is caused by insufficient outward remodeling and intimal hyperplasia. The exact pathophysiology remains unknown, but the inflammatory vascular response is thought to play an important role. In the present study we demonstrate that targeted liposomal delivery of prednisolone increases outward remodeling of the AVF in a murine model. Liposomes accumulate in the post-anastomotic area of the venous outflow tract in which the vascular pathology is most prominent in failed AVFs. On a histological level, we observed a reduction of lymphocytes and granulocytes in the vascular wall. In addition, a strong anti-inflammatory effect of liposomal prednisolone on macrophages was demonstrated in vitro. Therefore, treatment with liposomal prednisolone might be a valuable strategy to improve AVF maturation.
Collapse
Affiliation(s)
- ChunYu Wong
- Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden Medical Center, Leiden, The Netherlands
| | - Taisiya Bezhaeva
- Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden Medical Center, Leiden, The Netherlands
| | - Tonia C Rothuizen
- Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden Medical Center, Leiden, The Netherlands
| | - Josbert M Metselaar
- Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, The Netherlands.,Enceladus Pharmaceuticals BV, The Netherlands
| | - Margreet R de Vries
- Einthoven Laboratory for Experimental Vascular Medicine, Leiden Medical Center, Leiden, The Netherlands.,Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
| | - Floris P R Verbeek
- Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
| | | | - Anouk Wezel
- Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.,Leiden Academic Center for Drug Research, Leiden, The Netherlands
| | - Anton-Jan van Zonneveld
- Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden Medical Center, Leiden, The Netherlands
| | - Ton J Rabelink
- Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden Medical Center, Leiden, The Netherlands
| | - Paul H A Quax
- Einthoven Laboratory for Experimental Vascular Medicine, Leiden Medical Center, Leiden, The Netherlands.,Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
| | - Joris I Rotmans
- Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden Medical Center, Leiden, The Netherlands
| |
Collapse
|
38
|
Abstract
INTRODUCTION Ever since their discovery, liposomes have been radiolabeled to monitor their fate in vivo. Despite extensive preclinical studies, only a limited number of radiolabeled liposomal formulations have been examined in patients. Since they can play a crucial role in patient management, it is of importance to enable translation of radiolabeled liposomes into the clinic. AREAS COVERED Liposomes have demonstrated substantial advantages as drug delivery systems and can be efficiently radiolabeled. Potentially, radiolabeled drug-loaded liposomes form an elegant theranostic system, which can be tracked in vivo using single-photon emission computed tomography (SPECT) or positron emission tomography (PET) imaging. In this review, we discuss important aspects of liposomal research with a focus on the use of radiolabeled liposomes and their potential role in drug delivery and monitoring therapeutic effects. EXPERT OPINION Radiolabeled drug-loaded liposomes have been poorly investigated in patients and no radiolabeled liposomes have been approved for use in clinical practice. Evaluation of the risks, pharmacokinetics, pharmacodynamics and toxicity is necessary to meet pharmaceutical and commercial requirements. It remains to be demonstrated whether the results found in animal studies translate to humans before radiolabeled liposomes can be implemented into clinical practice.
Collapse
Affiliation(s)
- Tessa van der Geest
- a Department of Radiology and Nuclear Medicine , Radboud University Medical Center , Nijmegen , The Netherlands
| | - Peter Laverman
- a Department of Radiology and Nuclear Medicine , Radboud University Medical Center , Nijmegen , The Netherlands
| | - Josbert M Metselaar
- b Department of Experimental Molecular Imaging , University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH - Aachen University , Aachen , Germany.,c Department of Targeted Therapeutics , MIRA Institute, University of Twente , Enschede , The Netherlands
| | - Gert Storm
- c Department of Targeted Therapeutics , MIRA Institute, University of Twente , Enschede , The Netherlands.,d Department of Pharmaceutics , Utrecht Institute for Pharmaceutical Sciences, Utrecht University , Utrecht , The Netherlands
| | - Otto C Boerman
- a Department of Radiology and Nuclear Medicine , Radboud University Medical Center , Nijmegen , The Netherlands
| |
Collapse
|
39
|
Alaarg A, Zheng KH, van der Valk FM, da Silva AE, Versloot M, van Ufford LCQ, Schulte DM, Storm G, Metselaar JM, Stroes ESG, Hamers AAJ. Multiple pathway assessment to predict anti-atherogenic efficacy of drugs targeting macrophages in atherosclerotic plaques. Vascul Pharmacol 2016; 82:51-9. [PMID: 27189780 DOI: 10.1016/j.vph.2016.04.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2015] [Revised: 03/26/2016] [Accepted: 04/01/2016] [Indexed: 12/14/2022]
Abstract
BACKGROUND Macrophages play a central role in atherosclerosis development and progression, hence, targeting macrophage activity is considered an attractive therapeutic. Recently, we documented nanomedicinal delivery of the anti-inflammatory compound prednisolone to atherosclerotic plaque macrophages in patients, which did however not translate into therapeutic efficacy. This unanticipated finding calls for in-depth screening of drugs intended for targeting plaque macrophages. METHODS AND RESULTS We evaluated the effect of several candidate drugs on macrophage activity, rating overall performance with respect to changes in cytokine release, oxidative stress, lipid handling, endoplasmic reticulum (ER) stress, and proliferation of macrophages. Using this in vitro approach, we observed that the anti-inflammatory effect of prednisolone was counterbalanced by multiple adverse effects on other key pathways. Conversely, pterostilbene, T0901317 and simvastatin had an overall anti-atherogenic effect on multiple pathways, suggesting their potential for liposomal delivery. CONCLUSION This dedicated assay setup provides a framework for high-throughput assessment. Further in vivo studies are warranted to determine the predictive value of this macrophage-based screening approach and its potential value in nanomedicinal drug development for cardiovascular patients.
Collapse
Affiliation(s)
- Amr Alaarg
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands; Department of Biomaterials Science and Technology, Targeted Therapeutics section, MIRA Institute, University of Twente, Enschede, The Netherlands.
| | - Kang He Zheng
- Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
| | - Fleur M van der Valk
- Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
| | - Acarilia Eduardo da Silva
- Department of Biomaterials Science and Technology, Targeted Therapeutics section, MIRA Institute, University of Twente, Enschede, The Netherlands.
| | - Miranda Versloot
- Department of Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
| | - Linda C Quarles van Ufford
- Medicinal Chemistry & Chemical Biology - Biomolecular Analysis, Department of Pharmaceutical Sciences, Utrecht University, The Netherlands.
| | - Dominik M Schulte
- Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Internal Medicine I, UKSH, 24105 Kiel, Germany.
| | - Gert Storm
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands; Department of Biomaterials Science and Technology, Targeted Therapeutics section, MIRA Institute, University of Twente, Enschede, The Netherlands
| | - Josbert M Metselaar
- Department of Biomaterials Science and Technology, Targeted Therapeutics section, MIRA Institute, University of Twente, Enschede, The Netherlands; Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Aachen, Germany.
| | - Erik S G Stroes
- Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
| | - Anouk A J Hamers
- Department of Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
| |
Collapse
|
40
|
van Alem CMA, Bezhaeva T, Boonstra MC, Lalai RA, Koudijs A, Metselaar JM, Reinders MEJ, van Kooten C, Rotmans JI. TO009TARGETED DELIVERY OF LIPOSOMAL PREDNISOLONE AFTER RENAL ISCHEMIA REPERFUSION INJURY IN THE RAT. Nephrol Dial Transplant 2016. [DOI: 10.1093/ndt/gfw144.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Chen Y, van Steenbergen MJ, Li D, van de Dikkenberg JB, Lammers T, van Nostrum CF, Metselaar JM, Hennink WE. Polymeric Nanogels with Tailorable Degradation Behavior. Macromol Biosci 2016; 16:1122-37. [DOI: 10.1002/mabi.201600031] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2016] [Revised: 02/22/2016] [Indexed: 01/01/2023]
Affiliation(s)
- Yinan Chen
- Department of Pharmaceutics; Utrecht Institute for Pharmaceutical Sciences; Utrecht University; 3584 CG Utrecht The Netherlands
| | - Mies J. van Steenbergen
- Department of Pharmaceutics; Utrecht Institute for Pharmaceutical Sciences; Utrecht University; 3584 CG Utrecht The Netherlands
| | - Dandan Li
- Department of Pharmaceutics; Utrecht Institute for Pharmaceutical Sciences; Utrecht University; 3584 CG Utrecht The Netherlands
| | - Joep B. van de Dikkenberg
- Department of Pharmaceutics; Utrecht Institute for Pharmaceutical Sciences; Utrecht University; 3584 CG Utrecht The Netherlands
| | - Twan Lammers
- Department of Pharmaceutics; Utrecht Institute for Pharmaceutical Sciences; Utrecht University; 3584 CG Utrecht The Netherlands
- Department of Targeted Therapeutics; MIRA Institute for Biomedical Engineering and Technical Medicine; University of Twente; 7522 NB Enschede The Netherlands
- Department of Nanomedicine and Theranostics; Institute for Experimental Molecular Imaging; RWTH Aachen University Clinic; 52074 Aachen Germany
| | - Cornelus F. van Nostrum
- Department of Pharmaceutics; Utrecht Institute for Pharmaceutical Sciences; Utrecht University; 3584 CG Utrecht The Netherlands
| | - Josbert M. Metselaar
- Department of Targeted Therapeutics; MIRA Institute for Biomedical Engineering and Technical Medicine; University of Twente; 7522 NB Enschede The Netherlands
- Department of Nanomedicine and Theranostics; Institute for Experimental Molecular Imaging; RWTH Aachen University Clinic; 52074 Aachen Germany
| | - Wim E. Hennink
- Department of Pharmaceutics; Utrecht Institute for Pharmaceutical Sciences; Utrecht University; 3584 CG Utrecht The Netherlands
| |
Collapse
|
42
|
Matuszak J, Baumgartner J, Zaloga J, Juenet M, da Silva AE, Franke D, Almer G, Texier I, Faivre D, Metselaar JM, Navarro FP, Chauvierre C, Prassl R, Dézsi L, Urbanics R, Alexiou C, Mangge H, Szebeni J, Letourneur D, Cicha I. Nanoparticles for intravascular applications: physicochemical characterization and cytotoxicity testing. Nanomedicine (Lond) 2016; 11:597-616. [DOI: 10.2217/nnm.15.216] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
Aim: We report the physicochemical analysis of nanosystems intended for cardiovascular applications and their toxicological characterization in static and dynamic cell culture conditions. Methods: Size, polydispersity and ζ-potential were determined in 10 nanoparticle systems including liposomes, lipid nanoparticles, polymeric and iron oxide nanoparticles. Nanoparticle effects on primary human endothelial cell viability were monitored using real-time cell analysis and live-cell microscopy in static conditions, and in a flow model of arterial bifurcations. Results & conclusions: The majority of tested nanosystems were well tolerated by endothelial cells up to the concentration of 100 μg/ml in static, and up to 400 μg/ml in dynamic conditions. Pilot experiments in a pig model showed that intravenous administration of liposomal nanoparticles did not evoke the hypersensitivity reaction. These findings are of importance for future clinical use of nanosystems intended for intravascular applications.
Collapse
Affiliation(s)
- Jasmin Matuszak
- Cardiovascular Nanomedicine Unit, Section of Experimental Oncology and Nanomedicine (SEON), ENT-Department, University Hospital Erlangen, Glückstr. 10a, 91054 Erlangen, Germany
| | - Jens Baumgartner
- Department of Biomaterials, Max Planck Institute of Colloids & Interfaces, Science Park Golm, Potsdam, Germany
| | - Jan Zaloga
- Cardiovascular Nanomedicine Unit, Section of Experimental Oncology and Nanomedicine (SEON), ENT-Department, University Hospital Erlangen, Glückstr. 10a, 91054 Erlangen, Germany
| | - Maya Juenet
- Inserm U1148, LVTS, Paris Diderot University, Paris 13 University, Sorbonne Paris Cité, X. Bichat Hospital, Paris, France
| | - Acarília Eduardo da Silva
- Department of Targeted Therapeutics, MIRA Institute, University of Twente, Enschede, The Netherlands
| | | | - Gunter Almer
- Clinical Institute of Medical & Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
| | - Isabelle Texier
- CEA-LETI MINATEC/DTBS, Université Grenoble Alpes, Grenoble, France
| | - Damien Faivre
- Department of Biomaterials, Max Planck Institute of Colloids & Interfaces, Science Park Golm, Potsdam, Germany
| | - Josbert M Metselaar
- Department of Targeted Therapeutics, MIRA Institute, University of Twente, Enschede, The Netherlands
- Department of Experimental Molecular Imaging, University Clinic & Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Aachen, Germany
| | | | - Cédric Chauvierre
- Inserm U1148, LVTS, Paris Diderot University, Paris 13 University, Sorbonne Paris Cité, X. Bichat Hospital, Paris, France
| | - Ruth Prassl
- Institute of Biophysics, Medical University of Graz, Graz, Austria
| | - László Dézsi
- Nanomedicine Research & Education Center, Semmelweis University, Budapest, Hungary
| | | | - Christoph Alexiou
- Cardiovascular Nanomedicine Unit, Section of Experimental Oncology and Nanomedicine (SEON), ENT-Department, University Hospital Erlangen, Glückstr. 10a, 91054 Erlangen, Germany
| | - Harald Mangge
- Clinical Institute of Medical & Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
| | - János Szebeni
- Nanomedicine Research & Education Center, Semmelweis University, Budapest, Hungary
- SeroScience Ltd., Budapest, Hungary
| | - Didier Letourneur
- Inserm U1148, LVTS, Paris Diderot University, Paris 13 University, Sorbonne Paris Cité, X. Bichat Hospital, Paris, France
| | - Iwona Cicha
- Cardiovascular Nanomedicine Unit, Section of Experimental Oncology and Nanomedicine (SEON), ENT-Department, University Hospital Erlangen, Glückstr. 10a, 91054 Erlangen, Germany
| |
Collapse
|
43
|
Kroon J, Puhr M, Buijs JT, van der Horst G, Hemmer DM, Marijt KA, Hwang MS, Masood M, Grimm S, Storm G, Metselaar JM, Meijer OC, Culig Z, van der Pluijm G. Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer. Endocr Relat Cancer 2016; 23:35-45. [PMID: 26483423 PMCID: PMC4657186 DOI: 10.1530/erc-15-0343] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 10/19/2015] [Indexed: 12/17/2022]
Abstract
Resistance to docetaxel is a major clinical problem in advanced prostate cancer (PCa). Although glucocorticoids (GCs) are frequently used in combination with docetaxel, it is unclear to what extent GCs and their receptor, the glucocorticoid receptor (GR), contribute to the chemotherapy resistance. In this study, we aim to elucidate the role of the GR in docetaxel-resistant PCa in order to improve the current PCa therapies. GR expression was analyzed in a tissue microarray of primary PCa specimens from chemonaive and docetaxel-treated patients, and in cultured PCa cell lines with an acquired docetaxel resistance (PC3-DR, DU145-DR, and 22Rv1-DR). We found a robust overexpression of the GR in primary PCa from docetaxel-treated patients and enhanced GR levels in cultured docetaxel-resistant human PCa cells, indicating a key role of the GR in docetaxel resistance. The capability of the GR antagonists (RU-486 and cyproterone acetate) to revert docetaxel resistance was investigated and revealed significant resensitization of docetaxel-resistant PCa cells for docetaxel treatment in a dose- and time-dependent manner, in which a complete restoration of docetaxel sensitivity was achieved in both androgen receptor (AR)-negative and AR-positive cell lines. Mechanistically, we demonstrated down-regulation of Bcl-xL and Bcl-2 upon GR antagonism, thereby defining potential treatment targets. In conclusion, we describe the involvement of the GR in the acquisition of docetaxel resistance in human PCa. Therapeutic targeting of the GR effectively resensitizes docetaxel-resistant PCa cells. These findings warrant further investigation of the clinical utility of the GR antagonists in the management of patients with advanced and docetaxel-resistant PCa.
Collapse
Affiliation(s)
- Jan Kroon
- Department of UrologyLeiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The NetherlandsDepartment of Targeted TherapeuticsMIRA Institute for Biological Technology and Technical Medicine, University of Twente, Enschede, The NetherlandsDepartment of UrologyMedical University of Innsbruck, Innsbruck, AustriaDepartment of Clinical OncologyLeiden University Medical Center, Leiden, The NetherlandsDivision of Experimental MedicineImperial College London, London, UKDepartment of PharmaceuticsUtrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The NetherlandsDepartment of EndocrinologyLeiden University Medical Center, Leiden, The Netherlands Department of UrologyLeiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The NetherlandsDepartment of Targeted TherapeuticsMIRA Institute for Biological Technology and Technical Medicine, University of Twente, Enschede, The NetherlandsDepartment of UrologyMedical University of Innsbruck, Innsbruck, AustriaDepartment of Clinical OncologyLeiden University Medical Center, Leiden, The NetherlandsDivision of Experimental MedicineImperial College London, London, UKDepartment of PharmaceuticsUtrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The NetherlandsDepartment of EndocrinologyLeiden University Medical Center, Leiden, The Netherlands
| | - Martin Puhr
- Department of UrologyLeiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The NetherlandsDepartment of Targeted TherapeuticsMIRA Institute for Biological Technology and Technical Medicine, University of Twente, Enschede, The NetherlandsDepartment of UrologyMedical University of Innsbruck, Innsbruck, AustriaDepartment of Clinical OncologyLeiden University Medical Center, Leiden, The NetherlandsDivision of Experimental MedicineImperial College London, London, UKDepartment of PharmaceuticsUtrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The NetherlandsDepartment of EndocrinologyLeiden University Medical Center, Leiden, The Netherlands
| | - Jeroen T Buijs
- Department of UrologyLeiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The NetherlandsDepartment of Targeted TherapeuticsMIRA Institute for Biological Technology and Technical Medicine, University of Twente, Enschede, The NetherlandsDepartment of UrologyMedical University of Innsbruck, Innsbruck, AustriaDepartment of Clinical OncologyLeiden University Medical Center, Leiden, The NetherlandsDivision of Experimental MedicineImperial College London, London, UKDepartment of PharmaceuticsUtrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The NetherlandsDepartment of EndocrinologyLeiden University Medical Center, Leiden, The Netherlands
| | - Geertje van der Horst
- Department of UrologyLeiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The NetherlandsDepartment of Targeted TherapeuticsMIRA Institute for Biological Technology and Technical Medicine, University of Twente, Enschede, The NetherlandsDepartment of UrologyMedical University of Innsbruck, Innsbruck, AustriaDepartment of Clinical OncologyLeiden University Medical Center, Leiden, The NetherlandsDivision of Experimental MedicineImperial College London, London, UKDepartment of PharmaceuticsUtrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The NetherlandsDepartment of EndocrinologyLeiden University Medical Center, Leiden, The Netherlands
| | - Daniëlle M Hemmer
- Department of UrologyLeiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The NetherlandsDepartment of Targeted TherapeuticsMIRA Institute for Biological Technology and Technical Medicine, University of Twente, Enschede, The NetherlandsDepartment of UrologyMedical University of Innsbruck, Innsbruck, AustriaDepartment of Clinical OncologyLeiden University Medical Center, Leiden, The NetherlandsDivision of Experimental MedicineImperial College London, London, UKDepartment of PharmaceuticsUtrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The NetherlandsDepartment of EndocrinologyLeiden University Medical Center, Leiden, The Netherlands
| | - Koen A Marijt
- Department of UrologyLeiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The NetherlandsDepartment of Targeted TherapeuticsMIRA Institute for Biological Technology and Technical Medicine, University of Twente, Enschede, The NetherlandsDepartment of UrologyMedical University of Innsbruck, Innsbruck, AustriaDepartment of Clinical OncologyLeiden University Medical Center, Leiden, The NetherlandsDivision of Experimental MedicineImperial College London, London, UKDepartment of PharmaceuticsUtrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The NetherlandsDepartment of EndocrinologyLeiden University Medical Center, Leiden, The Netherlands
| | - Ming S Hwang
- Department of UrologyLeiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The NetherlandsDepartment of Targeted TherapeuticsMIRA Institute for Biological Technology and Technical Medicine, University of Twente, Enschede, The NetherlandsDepartment of UrologyMedical University of Innsbruck, Innsbruck, AustriaDepartment of Clinical OncologyLeiden University Medical Center, Leiden, The NetherlandsDivision of Experimental MedicineImperial College London, London, UKDepartment of PharmaceuticsUtrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The NetherlandsDepartment of EndocrinologyLeiden University Medical Center, Leiden, The Netherlands
| | - Motasim Masood
- Department of UrologyLeiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The NetherlandsDepartment of Targeted TherapeuticsMIRA Institute for Biological Technology and Technical Medicine, University of Twente, Enschede, The NetherlandsDepartment of UrologyMedical University of Innsbruck, Innsbruck, AustriaDepartment of Clinical OncologyLeiden University Medical Center, Leiden, The NetherlandsDivision of Experimental MedicineImperial College London, London, UKDepartment of PharmaceuticsUtrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The NetherlandsDepartment of EndocrinologyLeiden University Medical Center, Leiden, The Netherlands
| | - Stefan Grimm
- Department of UrologyLeiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The NetherlandsDepartment of Targeted TherapeuticsMIRA Institute for Biological Technology and Technical Medicine, University of Twente, Enschede, The NetherlandsDepartment of UrologyMedical University of Innsbruck, Innsbruck, AustriaDepartment of Clinical OncologyLeiden University Medical Center, Leiden, The NetherlandsDivision of Experimental MedicineImperial College London, London, UKDepartment of PharmaceuticsUtrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The NetherlandsDepartment of EndocrinologyLeiden University Medical Center, Leiden, The Netherlands
| | - Gert Storm
- Department of UrologyLeiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The NetherlandsDepartment of Targeted TherapeuticsMIRA Institute for Biological Technology and Technical Medicine, University of Twente, Enschede, The NetherlandsDepartment of UrologyMedical University of Innsbruck, Innsbruck, AustriaDepartment of Clinical OncologyLeiden University Medical Center, Leiden, The NetherlandsDivision of Experimental MedicineImperial College London, London, UKDepartment of PharmaceuticsUtrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The NetherlandsDepartment of EndocrinologyLeiden University Medical Center, Leiden, The Netherlands Department of UrologyLeiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The NetherlandsDepartment of Targeted TherapeuticsMIRA Institute for Biological Technology and Technical Medicine, University of Twente, Enschede, The NetherlandsDepartment of UrologyMedical University of Innsbruck, Innsbruck, AustriaDepartment of Clinical OncologyLeiden University Medical Center, Leiden, The NetherlandsDivision of Experimental MedicineImperial College London, London, UKDepartment of PharmaceuticsUtrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The NetherlandsDepartment of EndocrinologyLeiden University Medical Center, Leiden, The Netherlands
| | - Josbert M Metselaar
- Department of UrologyLeiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The NetherlandsDepartment of Targeted TherapeuticsMIRA Institute for Biological Technology and Technical Medicine, University of Twente, Enschede, The NetherlandsDepartment of UrologyMedical University of Innsbruck, Innsbruck, AustriaDepartment of Clinical OncologyLeiden University Medical Center, Leiden, The NetherlandsDivision of Experimental MedicineImperial College London, London, UKDepartment of PharmaceuticsUtrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The NetherlandsDepartment of EndocrinologyLeiden University Medical Center, Leiden, The Netherlands
| | - Onno C Meijer
- Department of UrologyLeiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The NetherlandsDepartment of Targeted TherapeuticsMIRA Institute for Biological Technology and Technical Medicine, University of Twente, Enschede, The NetherlandsDepartment of UrologyMedical University of Innsbruck, Innsbruck, AustriaDepartment of Clinical OncologyLeiden University Medical Center, Leiden, The NetherlandsDivision of Experimental MedicineImperial College London, London, UKDepartment of PharmaceuticsUtrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The NetherlandsDepartment of EndocrinologyLeiden University Medical Center, Leiden, The Netherlands
| | - Zoran Culig
- Department of UrologyLeiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The NetherlandsDepartment of Targeted TherapeuticsMIRA Institute for Biological Technology and Technical Medicine, University of Twente, Enschede, The NetherlandsDepartment of UrologyMedical University of Innsbruck, Innsbruck, AustriaDepartment of Clinical OncologyLeiden University Medical Center, Leiden, The NetherlandsDivision of Experimental MedicineImperial College London, London, UKDepartment of PharmaceuticsUtrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The NetherlandsDepartment of EndocrinologyLeiden University Medical Center, Leiden, The Netherlands
| | - Gabri van der Pluijm
- Department of UrologyLeiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The NetherlandsDepartment of Targeted TherapeuticsMIRA Institute for Biological Technology and Technical Medicine, University of Twente, Enschede, The NetherlandsDepartment of UrologyMedical University of Innsbruck, Innsbruck, AustriaDepartment of Clinical OncologyLeiden University Medical Center, Leiden, The NetherlandsDivision of Experimental MedicineImperial College London, London, UKDepartment of PharmaceuticsUtrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The NetherlandsDepartment of EndocrinologyLeiden University Medical Center, Leiden, The Netherlands
| |
Collapse
|
44
|
Underwood C, Pollitt CC, Metselaar JM, Laverman P, van Bloois L, van den Hoven JM, Storm G, van Eps AW. Distribution of technetium-99m PEG-liposomes during oligofructose-induced laminitis development in horses. Vet J 2015; 206:218-25. [PMID: 26403954 DOI: 10.1016/j.tvjl.2015.07.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2014] [Revised: 04/08/2015] [Accepted: 07/12/2015] [Indexed: 12/16/2022]
Abstract
Liposomes are phospholipid nanoparticles used for targeted drug delivery. This study aimed to determine whether intravenous liposomes accumulate in lamellar tissue during laminitis development in horses so as to assess their potential for targeted lamellar drug delivery. Polyethylene-glycol (PEG) coated liposomes were prepared according to the film hydration method and labelled using (99m)Tc-hexamethyl-propylene-amine-oxime. Six horses received 10 g/kg oligofructose via nasogastric tube to induce laminitis, and four control horses received water via nasogastric tube. All horses received 300 µmol (99m)Tc-PEG-liposomes (5.5 GBq) plus 5.5 µmol/kg PEG-liposomes by slow intravenous infusion. Scintigraphic imaging was performed at 0, 6 and 12 h post-infusion. Technetium-99m liposome uptake was measured in regions of interest over the hoof, fetlock and metacarpus. At the study end-point horses were euthanased, tissue samples collected and tissue liposome levels were calculated as the percentage of the injected dose of (99m)Tc-liposomes per kilogram of tissue. Data were analysed non-parametrically. All horses receiving oligofructose developed clinical and histological signs of laminitis. Technetium-99m liposome uptake in the hoof increased with time in laminitis horses (P = 0.04), but decreased with time in control horses (P = 0.01). Technetium-99m liposome levels in lamellar tissue from laminitis horses were 3.2-fold higher than controls (P = 0.02) and were also higher in laminitis vs. control skin, muscle, jejunum, colon, and kidney (P < 0.05). Liposomes accumulated in lamellar tissue during oligofructose-induced laminitis development and demonstrated potential for targeted lamellar drug delivery in acute laminitis. This study provides further evidence that lamellar inflammation occurs during laminitis development. Liposome accumulation also occurred in the skin, muscle, jejunum, colon and kidneys, suggesting systemic inflammation in this model.
Collapse
Affiliation(s)
- Claire Underwood
- Australian Equine Laminitis Research Unit, School of Veterinary Science, University of Queensland, Gatton, QLD 4343, Australia.
| | - Christopher C Pollitt
- Australian Equine Laminitis Research Unit, School of Veterinary Science, University of Queensland, Gatton, QLD 4343, Australia
| | - Josbert M Metselaar
- Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Aachen, Germany
| | - Peter Laverman
- Radboud University Medical Centre Nijmegen, The Netherlands
| | - Louis van Bloois
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), University of Utrecht, The Netherlands
| | | | - Gert Storm
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), University of Utrecht, The Netherlands
| | - Andrew W van Eps
- Australian Equine Laminitis Research Unit, School of Veterinary Science, University of Queensland, Gatton, QLD 4343, Australia
| |
Collapse
|
45
|
Kroon J, Buijs JT, van der Horst G, Cheung H, van der Mark M, van Bloois L, Rizzo LY, Lammers T, Pelger RC, Storm G, van der Pluijm G, Metselaar JM. Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth in vivo. Prostate 2015; 75:815-24. [PMID: 25663076 PMCID: PMC5006873 DOI: 10.1002/pros.22963] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/29/2014] [Accepted: 12/19/2014] [Indexed: 12/26/2022]
Abstract
BACKGROUND The inflammatory tumor microenvironment, and more specifically the tumor-associated macrophages, plays an essential role in the development and progression of prostate cancer towards metastatic bone disease. Tumors are often characterized by a leaky vasculature, which - combined with the prolonged circulation kinetics of liposomes - leads to efficient tumor localization of these drug carriers, via the so-called enhanced permeability and retention (EPR) -effect. In this study, we evaluated the utility of targeted, liposomal drug delivery of the glucocorticoid dexamethasone in a model of prostate cancer bone metastases. METHODS Tumor-bearing Balb-c nu/nu mice were treated intravenously with 0.2-1.0-5.0 mg/kg/week free- and liposomal DEX for 3-4 weeks and tumor growth was monitored by bioluminescent imaging. RESULTS Intravenously administered liposomes localize efficiently to bone metastases in vivo and treatment of established bone metastases with (liposomal) dexamethasone resulted in a significant inhibition of tumor growth up to 26 days after initiation of treatment. Furthermore, 1.0 mg/kg liposomal dexamethasone significantly outperformed 1.0 mg/kg free dexamethasone, and was found to be well-tolerated at clinically-relevant dosages that display potent anti-tumor efficacy. CONCLUSIONS Liposomal delivery of the glucocorticoid dexamethasone inhibits the growth of malignant bone lesions. We believe that liposomal encapsulation of dexamethasone offers a promising new treatment option for advanced, metastatic prostate cancer which supports further clinical evaluation.
Collapse
Affiliation(s)
- Jan Kroon
- Department of UrologyLeiden University Medical CenterLeidenThe Netherlands
- Department of Targeted TherapeuticsMIRA Institute for Biological Technology and Technical MedicineEnschedeThe Netherlands
| | - Jeroen T. Buijs
- Department of UrologyLeiden University Medical CenterLeidenThe Netherlands
| | | | - Henry Cheung
- Department of UrologyLeiden University Medical CenterLeidenThe Netherlands
| | | | - Louis van Bloois
- Department of PharmaceuticsUtrecht Institute for Pharmaceutical SciencesUtrecht UniversityUtrechtThe Netherlands
| | - Larissa Y. Rizzo
- Department of Experimental Molecular ImagingUniversity Clinic and Helmholtz Institute for Biomedical EngineeringRWTH‐Aachen UniversityAachenGermany
| | - Twan Lammers
- Department of Targeted TherapeuticsMIRA Institute for Biological Technology and Technical MedicineEnschedeThe Netherlands
- Department of PharmaceuticsUtrecht Institute for Pharmaceutical SciencesUtrecht UniversityUtrechtThe Netherlands
- Department of Experimental Molecular ImagingUniversity Clinic and Helmholtz Institute for Biomedical EngineeringRWTH‐Aachen UniversityAachenGermany
| | - Rob C. Pelger
- Department of UrologyLeiden University Medical CenterLeidenThe Netherlands
| | - Gert Storm
- Department of Targeted TherapeuticsMIRA Institute for Biological Technology and Technical MedicineEnschedeThe Netherlands
- Department of PharmaceuticsUtrecht Institute for Pharmaceutical SciencesUtrecht UniversityUtrechtThe Netherlands
| | | | - Josbert M. Metselaar
- Department of Targeted TherapeuticsMIRA Institute for Biological Technology and Technical MedicineEnschedeThe Netherlands
- Department of Experimental Molecular ImagingUniversity Clinic and Helmholtz Institute for Biomedical EngineeringRWTH‐Aachen UniversityAachenGermany
| |
Collapse
|
46
|
Terry SYA, Boerman OC, Gerrits D, Franssen GM, Metselaar JM, Lehmann S, Oyen WJG, Gerdes CA, Abiraj K. ¹¹¹In-anti-F4/80-A3-1 antibody: a novel tracer to image macrophages. Eur J Nucl Med Mol Imaging 2015; 42:1430-8. [PMID: 26012900 PMCID: PMC4502320 DOI: 10.1007/s00259-015-3084-8] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2015] [Accepted: 05/06/2015] [Indexed: 11/29/2022]
Abstract
Purpose Here, the expression of F4/80 on the cell surface of murine macrophages was exploited to develop a novel imaging tracer that could visualize macrophages in vivo. Methods The immunoreactive fraction and IC50 of anti-F4/80-A3-1, conjugated with diethylenetriaminepentaacetic acid (DTPA) and radiolabelled with 111In, were determined in vitro using murine bone marrow-derived macrophages. In vivo biodistribution studies were performed with 111In-anti-F4/80-A3-1 and isotype-matched control antibody 111In-rat IgG2b at 24 and 72 h post-injection (p.i.) in SCID/Beige mice bearing orthotopic MDA-MB-231 xenografts. In some studies mice were also treated with liposomal clodronate. Macrophage content in tissues was determined immunohistochemically. Micro-single photon emission computed tomography (SPECT)/CT images were also acquired. Results In vitro binding assays showed that 111In-anti-F4/80-A3-1 specifically binds F4/80 receptor-positive macrophages. The immunoreactivity of anti-F4/80-A3-1 was 75 % and IC50 was 0.58 nM. In vivo, injection of 10 or 100 μg 111In-anti-F4/80-A3-1 resulted in splenic uptake of 78 %ID/g and 31 %ID/g, respectively, and tumour uptake of 1.38 %ID/g and 4.08 %ID/g, respectively (72 h p.i.). Liposomal clodronate treatment reduced splenic uptake of 10 μg 111In-anti-F4/80-A3-1 from 248 %ID/g to 114 %ID/g and reduced 111In-anti-F4/80-A3-1 uptake in the liver and femur (24 h p.i.). Tracer retention in the blood and tumour uptake increased (24 h p.i.). Tumour uptake of 111In-anti-F4/80-A3-1 was visualized by microSPECT/CT. Macrophage density in the spleen and liver decreased in mice treated with liposomal clodronate. Uptake of 111In-rat IgG2b was lower in the spleen, liver and femur when compared to 111In-anti-F4/80-A3-1. Conclusion Radiolabelled anti-F4/80-A3-1 antibodies specifically localize in tissues infiltrated by macrophages in mice and can be used to visualize tumours. The liver and spleen act as antigen sink organs for macrophage-specific tracers. Electronic supplementary material The online version of this article (doi:10.1007/s00259-015-3084-8) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Samantha Y A Terry
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands,
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
van der Geest T, Metselaar JM, Gerrits D, van Lent PL, Storm G, Laverman P, Boerman OC. [(18)]F FDG PET/CT imaging to monitor the therapeutic effect of liposome-encapsulated prednisolone in experimental rheumatoid arthritis. J Control Release 2015; 209:20-6. [PMID: 25902038 DOI: 10.1016/j.jconrel.2015.04.019] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2015] [Revised: 04/14/2015] [Accepted: 04/15/2015] [Indexed: 11/25/2022]
Abstract
Current treatment of rheumatoid arthritis includes systemic administration of glucocorticoids. To improve joint targeting and anti-inflammatory efficacy these glucocorticoids are encapsulated in long-circulating liposomes. The present study aimed to monitor therapeutic effects of prednisolone (PLP)-containing PEG-liposomes in murine antigen-induced arthritis (AIA) using [(18)F]FDG PET/CT. Mono-articular arthritis was induced in male C57Bl6/J mice. At 0, 3, 7 and 12 days after arthritis induction, inflamed joints were macroscopically scored (0 = unaffected to 4 = immobile) and [(18)F]FDG PET/CT images were acquired. In a second experiment, to study the feasibility to monitor therapeutic effects of PLP encapsulating PEG-liposomes, mice were treated with a single i.v. injection of PLP-containing PEG-liposomes (10 mg/kg) or empty PEG-liposomes 3 days after arthritis induction. Inflamed joints were macroscopically scored and images were acquired at -3, 0, 4 and 9 days after treatment. PET images were analyzed quantitatively, and mice were dissected to allow histological analysis of the joints. With progression of arthritis, [(18)F]FDG uptake in inflamed joints increased significantly (day 0: 2.5 ± 0.9%ID/ml, day 7: 4.4 ± 0.4%ID/ml, p = 0.0159), while no changes were observed in unaffected paws (day 0: 2.5 ± 1.1%ID/ml, day 7: 2.7 ± 0.8%ID/ml, p = 0.3466). In the second experiment, macroscopic scoring revealed suppression of joint swelling after treatment with PLP-containing PEG-liposomes. In line with that, [(18)F]FDG uptake did not change in the treated mice (day -3: 1.9 ± 0.3%ID/ml, day 4: 2.2 ± 0.2%ID/ml, p = 0.3466), while it increased in mice that developed arthritis (day -3: 2.0 ± 0.2%ID/ml, day 4: 3.1 ± 0.6%ID/ml, p = 0.0225). Histological analysis confirmed therapeutic efficacy, which showed less inflammation (p = 0.0354) and bone erosion (p = 0.0298) in treated mice. These data show that [(18)F]FDG PET/CT could be used to monitor the progression of AIA and confirmed rapid and profound anti-inflammatory effects of PLP-containing PEG-liposomes that were also observed macroscopically and microscopically.
Collapse
Affiliation(s)
- Tessa van der Geest
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Geert Grooteplein zuid 10, 6525 GA Nijmegen, The Netherlands.
| | - Josbert M Metselaar
- Department of Targeted Therapeutics, MIRA Institute, University of Twente, Zuidhorst, 7500 AE Enschede, The Netherlands; Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Pauwelstrasse 30, 52074 Aachen, Germany.
| | - Danny Gerrits
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Geert Grooteplein zuid 10, 6525 GA Nijmegen, The Netherlands.
| | - Peter L van Lent
- Department of Experimental Rheumatology, Radboud university medical center, Geert Grooteplein 28, 6525 GA Nijmegen, The Netherlands.
| | - Gert Storm
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
| | - Peter Laverman
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Geert Grooteplein zuid 10, 6525 GA Nijmegen, The Netherlands.
| | - Otto C Boerman
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Geert Grooteplein zuid 10, 6525 GA Nijmegen, The Netherlands.
| |
Collapse
|
48
|
Lobatto ME, Calcagno C, Otten MJ, Millon A, Ramachandran S, Paridaans MPM, van der Valk FM, Storm G, Stroes ESG, Fayad ZA, Mulder WJM, Metselaar JM. Pharmaceutical development and preclinical evaluation of a GMP-grade anti-inflammatory nanotherapy. Nanomedicine 2015; 11:1133-40. [PMID: 25791805 DOI: 10.1016/j.nano.2015.02.020] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/08/2014] [Revised: 02/01/2015] [Accepted: 02/15/2015] [Indexed: 10/23/2022]
Abstract
UNLABELLED The present study describes the development of a good manufacturing practice (GMP)-grade liposomal nanotherapy containing prednisolone phosphate for the treatment of inflammatory diseases. After formulation design, GMP production was commenced which yielded consistent, stable liposomes sized 100nm±10nm, with a prednisolone phosphate (PLP) incorporation efficiency of 3%-5%. Pharmacokinetics and toxicokinetics of GMP-grade liposomal nanoparticles were evaluated in healthy rats, which were compared to daily and weekly administration of free prednisolone phosphate, revealing a long circulatory half-life with minimal side effects. Subsequently, non-invasive multimodal clinical imaging after liposomal nanotherapy's intravenous administration revealed anti-inflammatory effects on the vessel wall of atherosclerotic rabbits. The present program led to institutional review board approval for two clinical trials with patients with atherosclerosis. FROM THE CLINICAL EDITOR In drug discovery, bringing production to industrial scale is an essential process. In this article the authors describe the development of an anti-inflammatory nanoparticle according to good manufacturing practice. As a result, this paves the way for translating laboratory studies to clinical trials in humans.
Collapse
Affiliation(s)
- Mark E Lobatto
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, NY, NY, United States; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
| | - Claudia Calcagno
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, NY, NY, United States
| | - Maarten J Otten
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, NY, NY, United States
| | - Antoine Millon
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, NY, NY, United States; Department of Vascular Surgery, University Hospital of Lyon, Lyon, France
| | - Sarayu Ramachandran
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, NY, NY, United States
| | - Maarten P M Paridaans
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, NY, NY, United States
| | - Fleur M van der Valk
- Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
| | - Gert Storm
- Department of Targeted Therapeutics, MIRA Institute, University of Twente, Enschede, The Netherlands; Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
| | - Erik S G Stroes
- Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
| | - Zahi A Fayad
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, NY, NY, United States
| | - Willem J M Mulder
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, NY, NY, United States; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
| | - Josbert M Metselaar
- Department of Targeted Therapeutics, MIRA Institute, University of Twente, Enschede, The Netherlands; Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Aachen, Germany.
| |
Collapse
|
49
|
van der Valk FM, van Wijk DF, Lobatto ME, Verberne HJ, Storm G, Willems MCM, Legemate DA, Nederveen AJ, Calcagno C, Mani V, Ramachandran S, Paridaans MPM, Otten MJ, Dallinga-Thie GM, Fayad ZA, Nieuwdorp M, Schulte DM, Metselaar JM, Mulder WJM, Stroes ES. Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration. Nanomedicine 2015; 11:1039-46. [PMID: 25791806 DOI: 10.1016/j.nano.2015.02.021] [Citation(s) in RCA: 95] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/08/2014] [Revised: 02/11/2015] [Accepted: 02/19/2015] [Indexed: 02/08/2023]
Abstract
UNLABELLED Drug delivery to atherosclerotic plaques via liposomal nanoparticles may improve therapeutic agents' risk-benefit ratios. Our paper details the first clinical studies of a liposomal nanoparticle encapsulating prednisolone (LN-PLP) in atherosclerosis. First, PLP's liposomal encapsulation improved its pharmacokinetic profile in humans (n=13) as attested by an increased plasma half-life of 63h (LN-PLP 1.5mg/kg). Second, intravenously infused LN-PLP appeared in 75% of the macrophages isolated from iliofemoral plaques of patients (n=14) referred for vascular surgery in a randomized, placebo-controlled trial. LN-PLP treatment did however not reduce arterial wall permeability or inflammation in patients with atherosclerotic disease (n=30), as assessed by multimodal imaging in a subsequent randomized, placebo-controlled study. In conclusion, we successfully delivered a long-circulating nanoparticle to atherosclerotic plaque macrophages in patients, whereas prednisolone accumulation in atherosclerotic lesions had no anti-inflammatory effect. Nonetheless, the present study provides guidance for development and imaging-assisted evaluation of future nanomedicine in atherosclerosis. FROM THE CLINICAL EDITOR In this study, the authors undertook the first clinical trial using long-circulating liposomal nanoparticle encapsulating prednisolone in patients with atherosclerosis, based on previous animal studies. Despite little evidence of anti-inflammatory effect, the results have provided a starting point for future development of nanomedicine in cardiovascular diseases.
Collapse
Affiliation(s)
| | | | - Mark E Lobatto
- Department of Vascular Medicine, AMC, Amsterdam, The Netherlands.
| | - Hein J Verberne
- Department of Nuclear Medicine, AMC, Amsterdam, The Netherlands.
| | - Gert Storm
- Institute for Pharmaceutical Sciences UU, Utrecht, The Netherlands; Department of Targeted Therapeutics, MIRA Institute UT, Enschede, The Netherlands.
| | | | - Dink A Legemate
- Department of Vascular Surgery, AMC, Amsterdam, The Netherlands.
| | | | - Claudia Calcagno
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
| | - Venkatesh Mani
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
| | - Sarayu Ramachandran
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
| | - Maarten P M Paridaans
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
| | - Maarten J Otten
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
| | | | - Zahi A Fayad
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
| | - Max Nieuwdorp
- Department of Vascular Medicine, AMC, Amsterdam, The Netherlands.
| | - Dominik M Schulte
- Department of Vascular Medicine, AMC, Amsterdam, The Netherlands; Department of Internal Medicine I, UKSH, Kiel, Germany.
| | - Josbert M Metselaar
- Department of Targeted Therapeutics, MIRA Institute UT, Enschede, The Netherlands.
| | - Willem J M Mulder
- Department of Vascular Medicine, AMC, Amsterdam, The Netherlands; Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
| | - Erik S Stroes
- Department of Vascular Medicine, AMC, Amsterdam, The Netherlands.
| |
Collapse
|
50
|
Lobatto ME, Calcagno C, Millon A, Senders ML, Fay F, Robson PM, Ramachandran S, Binderup T, Paridaans MP, Sensarn S, Rogalla S, Gordon RE, Cardoso L, Storm G, Metselaar JM, Contag CH, Stroes ESG, Fayad ZA, Mulder WJ. Atherosclerotic plaque targeting mechanism of long-circulating nanoparticles established by multimodal imaging. ACS Nano 2015; 9:1837-47. [PMID: 25619964 PMCID: PMC4492477 DOI: 10.1021/nn506750r] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/18/2023]
Abstract
Atherosclerosis is a major cause of global morbidity and mortality that could benefit from novel targeted therapeutics. Recent studies have shown efficient and local drug delivery with nanoparticles, although the nanoparticle targeting mechanism for atherosclerosis has not yet been fully elucidated. Here we used in vivo and ex vivo multimodal imaging to examine permeability of the vessel wall and atherosclerotic plaque accumulation of fluorescently labeled liposomal nanoparticles in a rabbit model. We found a strong correlation between permeability as established by in vivo dynamic contrast enhanced magnetic resonance imaging and nanoparticle plaque accumulation with subsequent nanoparticle distribution throughout the vessel wall. These key observations will enable the development of nanotherapeutic strategies for atherosclerosis.
Collapse
Affiliation(s)
- Mark E. Lobatto
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York 10029, United States
- Department of Vascular Medicine, Academic Medical Center, Amsterdam, Meibergdreef 9,1105 AZ, The Netherlands
| | - Claudia Calcagno
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York 10029, United States
| | - Antoine Millon
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York 10029, United States
- Department of Vascular Surgery, University Hospital of Lyon, 69000 Lyon, France
| | - Max L. Senders
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York 10029, United States
| | - Francois Fay
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York 10029, United States
| | - Philip M. Robson
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York 10029, United States
| | - Sarayu Ramachandran
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York 10029, United States
| | - Tina Binderup
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York 10029, United States
- Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet & University of Copenhagen, 2200 Copenhagen, Denmark
| | - Maarten P.M. Paridaans
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York 10029, United States
| | - Steven Sensarn
- Departments of Radiology, Pediatrics and the Molecular Imaging Program, Stanford University, Stanford, California 94305, United States
| | - Stephan Rogalla
- Departments of Radiology, Pediatrics and the Molecular Imaging Program, Stanford University, Stanford, California 94305, United States
| | - Ronald E. Gordon
- Department of Pathology, Mount Sinai Hospital, One Gustave L. Levy Place, New York, New York 10029, United States
| | - Luis Cardoso
- Department of Biomedical Engineering, The City College of New York, New York, New York 10031, United States
| | - Gert Storm
- Department of Targeted Therapeutic, MIRA Institute, University of Twente, Enschede, 7500 AE, The Netherlands
- Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3512 JE, The Netherlands
| | - Josbert M. Metselaar
- Department of Targeted Therapeutic, MIRA Institute, University of Twente, Enschede, 7500 AE, The Netherlands
| | - Christopher H. Contag
- Departments of Radiology, Pediatrics and the Molecular Imaging Program, Stanford University, Stanford, California 94305, United States
| | - Erik S. G. Stroes
- Department of Vascular Medicine, Academic Medical Center, Amsterdam, Meibergdreef 9,1105 AZ, The Netherlands
| | - Zahi A. Fayad
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York 10029, United States
| | - Willem J.M. Mulder
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York 10029, United States
- Department of Vascular Medicine, Academic Medical Center, Amsterdam, Meibergdreef 9,1105 AZ, The Netherlands
- Address correspondence to
| |
Collapse
|